Amedeo Smart

Free Medical Literature Service

 

Amedeo

Bacterial Infections and Mycoses
  Free Subscription

Articles published in
Antimicrob Agents Chemother
    December 2025
  1. APPLEBACH E, Amburgey-Crovetti K, Bakotic WL, Adhikari TB, et al
    Prevalence and diversity of antifungal resistance in Fusarium isolates across clinical and agricultural settings in the United States.
    Antimicrob Agents Chemother. 2025;69:e0120825.
    >> Share

  2. BLEICK CR, Van Helden SR, Berti AD, Richa R, et al
    Optimizing phage-antibiotic combinations: impact of administration order against daptomycin non-susceptible (DNS) MRSA clinical isolates.
    Antimicrob Agents Chemother. 2025;69:e0069925.
    >> Share

  3. JUAN C-H, Chou S-H, Chuang C, Lin S-N, et al
    Carbapenems versus non-carbapenems as definitive treatment for hypervirulent Klebsiella pneumoniae bacteremia in Taiwan.
    Antimicrob Agents Chemother. 2025;69:e0084625.
    >> Share

  4. HAHN MM, Anderson MS, Snyder M, Du W, et al
    Pharmacokinetic modeling and efficacy of ceftobiprole medocaril against pneumonic tularemia in cynomolgus macaques.
    Antimicrob Agents Chemother. 2025;69:e0127825.
    >> Share

  5. EDWARDS B, Ripperton R, Tilley A, Chastain DB, et al
    Insights into current coccidioidomycosis therapeutic pathways.
    Antimicrob Agents Chemother. 2025;69:e0146525.
    >> Share

  6. NODARI CS, Bai Q, Cayo R, Streling AP, et al
    ISAba1-mediated bla(ADC) disruption restores third-generation cephalosporin susceptibility in a clinical Acinetobacter baumannii isolate.
    Antimicrob Agents Chemother. 2025;69:e0070725.
    >> Share

  7. CADENAS-JIMENEZ I, Gonzalez-Diaz A, Berbel D, Costa-Primo R, et al
    First report of a DIM-1-producing Pseudomonas aeruginosa in Spain: genomic characterization and resistance determinants.
    Antimicrob Agents Chemother. 2025;69:e0131125.
    >> Share

  8. HESELPOTH RD, Euler CW, Fischetti VA
    Second-generation lysocins as therapeutics for treating Pseudomonas aeruginosa infections.
    Antimicrob Agents Chemother. 2025;69:e0131225.
    >> Share

  9. RODRIGUEZ-OCHOA JL, Sauco-Carballo C, Perez-Palacios P, Merino-Bohorquez V, et al
    Pharmacokinetic/pharmacodynamic optimization of temocillin treatment against CTX-M-15-producing Klebsiella pneumoniae isolates in a hollow-fiber infection model.
    Antimicrob Agents Chemother. 2025;69:e0094625.
    >> Share

  10. ALVARADO-OROSCO N, Gomis-Font MA, Sastre-Femenia MA, Ribera Ortiz S, et al
    First nationwide survey on Pseudomonas aeruginosa in Bolivia: susceptibility profiles, resistome, and genomic epidemiology.
    Antimicrob Agents Chemother. 2025;69:e0116325.
    >> Share

  11. WANGCHINDA W, Wu JY, Abbo LM, Ackley R, et al
    Effectiveness of imipenem-relebactam for multidrug-resistant Pseudomonas aeruginosa in pneumonia and bloodstream infections in the United States (MIRAGE).
    Antimicrob Agents Chemother. 2025;69:e0132525.
    >> Share

  12. FU Y, Zhang Y, Zhao J, Xie J, et al
    Emergence of co-resistance to imipenem/relebactam and ceftazidime/avibactam in clinical Klebsiella pneumoniae ST11 clone due to KPC-2 N132S and CTX-M-65 S130G/P167S substitutions.
    Antimicrob Agents Chemother. 2025;69:e0089125.
    >> Share

  13. SLAIN N, Lucas K, Kunz Coyne AJ
    Comparison between cefepime and carbapenem therapy for deep-seated AmpC-producing Enterobacterales infections: a propensity-weighted retrospective cohort study.
    Antimicrob Agents Chemother. 2025;69:e0092825.
    >> Share

  14. VANACHAYANGKUL P, Ruamsap N, Caridha D, Imerbsin R, et al
    Preclinical in vitro and in vivo evaluation of omadacycline against multidrug-resistant Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025;69:e0093225.
    >> Share

  15. PAI MP, Cojutti PG, Gatti M, Rinaldi M, et al
    Keeping the horse with the cart: are we underdosing tazobactam even when using continuous-infusion ceftolozane/tazobactam for effectively preventing resistance development by ESBL-producing Enterobacterales?
    Antimicrob Agents Chemother. 2025;69:e0121525.
    >> Share

  16. GONZALEZ-PINTO L, Gomis-Font MA, Perez-Rodriguez G, Blanco-Martin T, et al
    Contribution of mutational resistance mechanisms and acquired beta-lactamases to cefiderocol/xeruborbactam susceptibility in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2025;69:e0104825.
    >> Share

  17. UPTON CM, Calderin JM, Diacon AH, Boeree MJ, et al
    Cerebrospinal fluid penetration of cycloserine/terizidone and clofazimine in patients with pulmonary TB.
    Antimicrob Agents Chemother. 2025;69:e0093125.
    >> Share

  18. TAKEI K, Kanamori H, Sakata R, Ogawa M, et al
    High-risk clonal expansion of IMP-producing Enterobacter cloacae complex in regional Japanese healthcare settings.
    Antimicrob Agents Chemother. 2025;69:e0095325.
    >> Share

  19. CUI Y, Feng X, Wang J, Liu L, et al
    Construction and assessment of a predictive framework for Enterobacterales bloodstream infection in real-world adult onco-hematology patients using Lasso-Cox regression.
    Antimicrob Agents Chemother. 2025;69:e0097325.
    >> Share

  20. BENAVENT E, Lora-Tamayo J, Ulldemolins M, Pons-Oltra P, et al
    Efficacy, safety, and population pharmacokinetics of a single 1500mg dose of dalbavancin for short-term therapy in patients with chronic prosthetic joint infections.
    Antimicrob Agents Chemother. 2025;69:e0077325.
    >> Share

  21. YOUSSEF EG, Gebremariam T, Gu Y, Patterson H, et al
    Efficacy assessments of EL219, a next-generation polyene antifungal, in immunosuppressed mice infected with drug-sensitive and drug-resistant Aspergillus isolates.
    Antimicrob Agents Chemother. 2025 Dec 5:e0140025. doi: 10.1128/aac.01400.
    >> Share

  22. ABDELSATTAR AS, Kikiowo B, Abutaleb NS, Dove AS, et al
    Repurposing epetraborole to combat Neisseria gonorrhoeae and Chlamydia trachomatis infections.
    Antimicrob Agents Chemother. 2025 Dec 5:e0144525. doi: 10.1128/aac.01445.
    >> Share

    November 2025
  23. FUNK OG, Li J, Khan I, Cusumano JA, et al
    Ceftobiprole alone versus ampicillin-ceftriaxone against borderline-penicillin-resistant, ampicillin-susceptible, and vancomycin-resistant Enterococcus faecalis isolates.
    Antimicrob Agents Chemother. 2025 Nov 24:e0105025. doi: 10.1128/aac.01050.
    >> Share

  24. LAVOIE T, Sierra T, Daffinee K, Pogue JM, et al
    Unlocking potentials: the impact of meropenem, meropenem-vaborbactam, and ceftazidime-avibactam in combating carbapenem-resistant Enterobacter cloacae.
    Antimicrob Agents Chemother. 2025 Nov 19:e0090625. doi: 10.1128/aac.00906.
    >> Share

  25. DARNELL RL, Knottenbelt MK, Rose OE, Cleary CSB, et al
    Prolonged exposure to teixobactin generates cross-tolerance to other cell wall-targeting antimicrobials in Enterococcus faecalis.
    Antimicrob Agents Chemother. 2025 Nov 18:e0062925. doi: 10.1128/aac.00629.
    >> Share

  26. HE G, Zeng S, Banki LT, Zhou W, et al
    Clinical emergence of inducible macrolide resistance mediated by acquired erm(41) C28T mutation in Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2025 Nov 6:e0115325. doi: 10.1128/aac.01153.
    >> Share

  27. KOCER K, My TN, Sy BT, Gopel L, et al
    Efficacy of cefiderocol in combination with xeruborbactam versus taniborbactam against cefiderocol-resistant NDM-producing Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2025;69:e0085725.
    >> Share

  28. ALSHIRAIHI IM, Lam H, Troyer BT, Tran KN, et al
    Characterization of new mouse models of acute and chronic Mycobacterium abscessus infection for antimicrobial drug screening.
    Antimicrob Agents Chemother. 2025;69:e0047525.
    >> Share

  29. WIEDERHOLD NP
    Case Commentary: Successful use of olorofim for the treatment of multi-drug-resistant Lomentospora prolificans infection in a child.
    Antimicrob Agents Chemother. 2025;69:e0107225.
    >> Share

  30. AOKI W, Uwamino Y, Kubota H, Kamoshita Y, et al
    Evaluation of in vitro efficacy of aztreonam-nacubactam and cefepime-nacubactam against clinical isolates of Stenotrophomonas maltophilia.
    Antimicrob Agents Chemother. 2025;69:e0075525.
    >> Share

  31. POUYA N, Finch NA, Granillo A, Bhimraj A, et al
    Pharmacokinetics of sulbactam-durlobactam in patients with Acinetobacter baumannii ventriculitis: a report of two cases.
    Antimicrob Agents Chemother. 2025;69:e0067425.
    >> Share

  32. COJUTTI PG, Pai MP, Gatti M, Rinaldi M, et al
    Targeting Pseudomonas aeruginosa resistance at the exposure frontier: a population PK/PD blueprint for ceftolozane/tazobactam continuous infusion.
    Antimicrob Agents Chemother. 2025;69:e0104225.
    >> Share

  33. KUNZ COYNE AJ, Gray R, May E, Curry H, et al
    Molecular and pharmacodynamic insights into beta-lactam therapy for high-inoculum Enterobacter cloacae complex infections.
    Antimicrob Agents Chemother. 2025;69:e0117025.
    >> Share

  34. WANG C, Feng Y, Zong Z
    Colistin heteroresistance in Enterobacter due to base heterozygosity at certain phoP and phoQ locations.
    Antimicrob Agents Chemother. 2025;69:e0071325.
    >> Share

  35. LODISE TP, Min J, Nathanson BH, Yucel E, et al
    Comparison of early treatment with ceftolozane/tazobactam versus polymyxin-based therapy of pneumonia due to MDR Pseudomonas aeruginosa (PUMA).
    Antimicrob Agents Chemother. 2025;69:e0056925.
    >> Share

  36. CHEN B, Chen Y, Chen M, Mao Y, et al
    Population pharmacokinetics and Monte Carlo-based dosing optimization of trimethoprim-sulfamethoxazole.
    Antimicrob Agents Chemother. 2025;69:e0051925.
    >> Share

  37. FORTINI M, Jones TW, Grams TR, Mehra S, et al
    Successful use of olorofim for the treatment of Lomentospora prolificans knee tendonitis, synovitis, and concomitant osteomyelitis in an immunocompetent child.
    Antimicrob Agents Chemother. 2025;69:e0060225.
    >> Share

  38. MOHAMAD M, Hurst MM, Elkrewi E, Randall CP, et al
    Nature of bacitracin resistance in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2025 Nov 4:e0087525. doi: 10.1128/aac.00875.
    >> Share

    October 2025
  39. HODBERT E, Lemenand O, Thibaut S, Coeffic T, et al
    Exploring multidrug resistance patterns in community-acquired Escherichia coli urinary tract infections with machine learning.
    Antimicrob Agents Chemother. 2025 Oct 31:e0042225. doi: 10.1128/aac.00422.
    >> Share

  40. SUN L, Lei T, Liu Y, Lu S, et al
    In vivo development of elevated linezolid resistance mediated by a deletion in ribosomal protein L3 in clinical Enterococcus faecium.
    Antimicrob Agents Chemother. 2025 Oct 28:e0087125. doi: 10.1128/aac.00871.
    >> Share

  41. XING Y, Bian M, Huang X, Lv B, et al
    Genome-wide screen reveals glycerol-induced aminoglycoside potentiation against Staphylococcus aureus via boosting GlpK-initiated energy metabolism.
    Antimicrob Agents Chemother. 2025 Oct 23:e0093825. doi: 10.1128/aac.00938.
    >> Share

  42. MARCH VFA, Zwyer M, Loiseau C, Brites D, et al
    Variability in intrinsic drug tolerance in Mycobacterium tuberculosis corresponds with phylogenetic lineage.
    Antimicrob Agents Chemother. 2025 Oct 21:e0099625. doi: 10.1128/aac.00996.
    >> Share

  43. SHAW S, Pragasam AK, Chowdhury G, Samanta P, et al
    Genomic portrayal of emerging carbapenem-resistant El Tor variant Vibrio cholerae O1.
    Antimicrob Agents Chemother. 2025 Oct 17:e0074025. doi: 10.1128/aac.00740.
    >> Share

  44. FRIAES A, Mamede R, Santos B, Marrao G, et al
    Increase of macrolide resistance among Streptococcus pyogenes pharyngitis driven by a mef(A)-msr(D)/emm2-ST55 lineage in Portugal (2014-2019).
    Antimicrob Agents Chemother. 2025 Oct 10:e0096825. doi: 10.1128/aac.00968.
    >> Share

  45. ALVARADO CASAS ML, Triana Diaz JA, Montilla-Escudero E, Prada Cardozo DA, et al
    Genomic epidemiology of Colombian resistant Candida auris isolates.
    Antimicrob Agents Chemother. 2025 Oct 7:e0072525. doi: 10.1128/aac.00725.
    >> Share

  46. DONG X, Xiang Y, Li Y, Zhang Y, et al
    Lineage-specific evolution and resistance-virulence divergence in Klebsiella pneumoniae ST268: a global population genomic analysis.
    Antimicrob Agents Chemother. 2025;69:e0070325.
    >> Share

  47. MOJICA MF, Becka SA, Edwards M, Myers C, et al
    Burkholderia pseudomallei PenI beta-lactamase and variants are potently inhibited by taniborbactam.
    Antimicrob Agents Chemother. 2025;69:e0078725.
    >> Share

  48. RAKA V, Jangra M, Kaur P, Dadwal R, et al
    Preclinical evaluation of tridecaptin M: in vitro and in vivo efficacy against colistin-resistant Gram-negative bacterial pathogens and pharmacokinetics.
    Antimicrob Agents Chemother. 2025;69:e0108325.
    >> Share

  49. ALARCON RIOS AC, Zwep LB, Vriesendorp B, Knibbe CAJ, et al
    Colistin resistance dynamics in Pseudomonas aeruginosa under biofilm and planktonic growth.
    Antimicrob Agents Chemother. 2025;69:e0042125.
    >> Share

  50. WAN T-W, Shintani M, Kojima KK, Moriguchi N, et al
    Transposition of Tn552-II (a Tn552 derivative) to the conjugative pCtra plasmid family in pediatric multidrug-resistant community-associated MRSA.
    Antimicrob Agents Chemother. 2025;69:e0064725.
    >> Share

  51. LI Y, Roberts JA, Abdul-Aziz MH, Sime FB, et al
    Continuous or extended vs intermittent infusions of beta-lactam antibiotics in ICU patients with pneumonia: a systematic review and meta-analysis of randomized controlled trials.
    Antimicrob Agents Chemother. 2025;69:e0073225.
    >> Share

  52. POGUE JM, Harrington J, Wangchinda W, Kaye KS, et al
    New Perspectives on Antimicrobial Agents: Sulbactam-durlobactam.
    Antimicrob Agents Chemother. 2025;69:e0108624.
    >> Share

  53. ZHANG Y, Guo S, Jiang L, Wang S, et al
    Mechanistic blockade of Pseudomonas aeruginosa type III secretion by a monoclonal antibody targeting the pore size-determining domain of PcrV.
    Antimicrob Agents Chemother. 2025;69:e0040525.
    >> Share

    September 2025
  54. PEROUTKA-BIGUS N, Scherman MS, Kaya F, Waidyarachchi SL, et al
    Sterilizing activity of spectinamide MBX-4888A when replacing linezolid in the Nix-TB regimen in the relapsing BALB/c mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 30:e0118325. doi: 10.1128/aac.01183.
    >> Share

  55. VENA A, Bartalucci C, Muccio M, Tiseo G, et al
    Comparative effectiveness of echinocandins and liposomal amphotericin B for fluconazole-resistant Candida parapsilosis bloodstream infections.
    Antimicrob Agents Chemother. 2025 Sep 30:e0035525. doi: 10.1128/aac.00355.
    >> Share

  56. SHINOHARA T, Wada A, Abe M, Oiki S, et al
    A zinc-chelating cyclic alkyl polyamine compound is efficient and safe in a murine model of multidrug-resistant Candida auris infection.
    Antimicrob Agents Chemother. 2025 Sep 26:e0085625. doi: 10.1128/aac.00856.
    >> Share

  57. SINGH S, Devine M, Gumbo T, Srivastava S, et al
    Epetraborole pharmacokinetics/pharmacodynamics in the hollow fiber system model of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0048125. doi: 10.1128/aac.00481.
    >> Share

  58. RUPASINGHE P, Ismail N, Mulders W, Warren RM, et al
    In vitro exposure to clofazimine can select for delamanid and pretomanid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0111325. doi: 10.1128/aac.01113.
    >> Share

  59. BALDIN VP, Harding CL, Quach D, Sugie J, et al
    Thienopyrimidine amide analogs target MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 22:e0098025. doi: 10.1128/aac.00980.
    >> Share

  60. ZENG Q, Huang H, Lu J, Wu L, et al
    Comparison of different colistin sulfate regimens for carbapenem-resistant gram-negative bacteria pneumonia in neurocritical care patients: a retrospective cohort study.
    Antimicrob Agents Chemother. 2025 Sep 22:e0064425. doi: 10.1128/aac.00644.
    >> Share

  61. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
    Deconvoluting drug interactions using M. tuberculosis physiologic processes: transcriptional disaggregation of the BPaL regimen in vivo.
    Antimicrob Agents Chemother. 2025 Sep 18:e0049225. doi: 10.1128/aac.00492.
    >> Share

  62. MARTIN-VICENTE A, Nywening AV, Xie J, Thorn HI, et al
    Genetic analysis of common triazole resistance mechanisms in a collection of Aspergillus lentulus clinical isolates from the United States.
    Antimicrob Agents Chemother. 2025 Sep 12:e0069025. doi: 10.1128/aac.00690.
    >> Share

  63. TURNER AM, Kinsella P, Miller WR, Carter GP, et al
    Therapeutic approach to difficult-to-treat multidrug-resistant enterococcal infections.
    Antimicrob Agents Chemother. 2025 Sep 11:e0106024. doi: 10.1128/aac.01060.
    >> Share

  64. KIRUBAKAR G, Johnston L, Nae Rin Lee B, Russell DG, et al
    Incorporation of macrophage immune stresses into an intracellular assay of drug tolerance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Sep 11:e0079525. doi: 10.1128/aac.00795.
    >> Share

  65. AVERY LM, Edwards M, Yi F, Moeck G, et al
    Assessment of human exposures of cefepime-taniborbactam against cefepime-resistant Enterobacterales and Pseudomonas aeruginosa in a 7-day hollow fiber infection model.
    Antimicrob Agents Chemother. 2025;69:e0001725.
    >> Share

  66. CASTILLO-RAMIREZ S, Aguilar-Vera A, Kumar A, Evans B, et al
    Acinetobacter baumannii: much more than a human pathogen.
    Antimicrob Agents Chemother. 2025;69:e0080125.
    >> Share

  67. FURLAN GHF, Oliveira DAS, Bertoluci DFDF, Gomes TA, et al
    Assessment of TB47 as a potential novel therapeutic agent: in vitro and in vivo efficacy against Mycobacterium leprae.
    Antimicrob Agents Chemother. 2025;69:e0031825.
    >> Share

  68. RESENDIZ-GALVAN JE, Arora PR, Lokhande RV, Udwadia ZF, et al
    Evaluation of cycloserine dose regimens in an Indian cohort with multidrug-resistant tuberculosis: a population pharmacokinetic analysis.
    Antimicrob Agents Chemother. 2025 Sep 2:e0010125. doi: 10.1128/aac.00101.
    >> Share

    August 2025
  69. WALSH TJ, Coleman CI, Blissett R, Prawitz T, et al
    Cost-effectiveness of olorofim in the treatment of invasive aspergillosis in patients with limited suitable alternative treatment options: a US payer perspective.
    Antimicrob Agents Chemother. 2025 Aug 27:e0057025. doi: 10.1128/aac.00570.
    >> Share

  70. ZHANG M, Allen R, Ames L, Engelhart CA, et al
    Microbiological evidence for the trisubstituted benzimidazoles targeting MmpL3 in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Aug 19:e0036825. doi: 10.1128/aac.00368.
    >> Share

  71. REITLER P, DeJarnette CA, Kumar R, Tucker KM, et al
    A screen to identify antifungal antagonists reveals a variety of pharmacotherapies that induce echinocandin tolerance in Candida albicans.
    Antimicrob Agents Chemother. 2025 Aug 18:e0048425. doi: 10.1128/aac.00484.
    >> Share

  72. BARKER KS, Santana DJ, Zhang Q, Peters TL, et al
    Mutations in TAC1B drive increased CDR1 and MDR1 expression and azole resistance in Candida auris.
    Antimicrob Agents Chemother. 2025 Aug 18:e0030025. doi: 10.1128/aac.00300.
    >> Share

  73. MUSHER DM
    Amoxicillin vs. ceftriaxone to treat pneumonia caused by amoxicillin-non-susceptible Streptococcus pneumoniae.
    Antimicrob Agents Chemother. 2025 Aug 13:e0078025. doi: 10.1128/aac.00780.
    >> Share

  74. ISMAIL N, Sirgel F, Omar SV, Omar S, et al
    Unpacking bedaquiline heteroresistance: the importance of intermediate profiles for phenotypic drug susceptibility testing.
    Antimicrob Agents Chemother. 2025;69:e0035625.
    >> Share

  75. LE MOIGNE V, Bitar M, Arthur M, Mainardi J-L, et al
    The addition of amoxicillin improves the efficacy of the imipenem-avibactam combination against Mycobacterium abscessus in a mouse model of infection.
    Antimicrob Agents Chemother. 2025;69:e0053425.
    >> Share

  76. BUYUKYANBOLU E, Argotsinger J, Beck ET, Chamberland RR, et al
    Activity of ampicillin-sulbactam, sulbactam-durlobactam, and comparators against Acinetobacter baumannii-calcoaceticus complex strains isolated from respiratory and bloodstream sources: results from ACNBio study.
    Antimicrob Agents Chemother. 2025;69:e0037925.
    >> Share

  77. KUBIN CJ, Garzia C, Uhlemann A-C
    Acinetobacter baumannii treatment strategies: a review of therapeutic challenges and considerations.
    Antimicrob Agents Chemother. 2025;69:e0106324.
    >> Share

  78. GONG J-J, Huang I-H, Hung Y, Chen Y-W, et al
    Combination of mitomycin C and low-dose metronidazole synergistically against Clostridioides difficile infection and recurrence prevention.
    Antimicrob Agents Chemother. 2025;69:e0051525.
    >> Share

  79. OJHA S, Chatterjee P, Beuria TK
    Inhibition of efflux pumps by FDA-approved drugs oxiconazole and sertaconazole restores antibiotic susceptibility in multidrug-resistant S. aureus.
    Antimicrob Agents Chemother. 2025 Aug 4:e0032025. doi: 10.1128/aac.00320.
    >> Share

  80. GOMI S, Price E, Burgoyne H, Faozia S, et al
    Omadacycline exhibits anti-inflammatory properties and improves survival in a murine model of post-influenza MRSA pneumonia.
    Antimicrob Agents Chemother. 2025 Aug 4:e0046925. doi: 10.1128/aac.00469.
    >> Share

    July 2025
  81. VAN SCHALKWYK M, Bekker A, Decloedt E, Wang J, et al
    Pharmacokinetics of first-line tuberculosis drugs rifampin, isoniazid, ethambutol, and pyrazinamide during pregnancy and postpartum with and without efavirenz-based antiretroviral treatment: IMPAACT P1026s study.
    Antimicrob Agents Chemother. 2025 Jul 31:e0005225. doi: 10.1128/aac.00052.
    >> Share

  82. LIANG L, Quigley J, Theriault M, Iinishi A, et al
    A chlorinated diketopiperazine antibiotic targets Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Jul 31:e0036925. doi: 10.1128/aac.00369.
    >> Share

  83. WU Y, Dai Y, Lu H, Jiang X, et al
    Osh2 mediates Candida species resistance to miltefosine by regulating zymosterol accumulation.
    Antimicrob Agents Chemother. 2025 Jul 23:e0042725. doi: 10.1128/aac.00427.
    >> Share

  84. BARKER KS, Patterson HP, Morschhauser J, Cuomo CA, et al
    Mutations in transcription factors that confer fluconazole resistance also confer reduced susceptibility to manogepix in Candida auris (Candidozyma auris), Candida albicans, Candida parapsilosis, and Candida glabrata (Nakaseomyces glabratus).
    Antimicrob Agents Chemother. 2025 Jul 23:e0068025. doi: 10.1128/aac.00680.
    >> Share

  85. HIDROSOLLO JH, Liao H-W, Yap CH, James JJ, et al
    Indolenine-substituted pyrazole derivative 4e inhibits planktonic Staphylococcus lugdunensis growth and biofilm formation by disrupting purine biosynthesis and compromising cell wall and membrane integrity.
    Antimicrob Agents Chemother. 2025 Jul 23:e0019925. doi: 10.1128/aac.00199.
    >> Share

  86. FANG Y, Song M, Zhang Y, Wu Z, et al
    Evolution of XDR Pseudomonas aeruginosa ST463 strains with two plasmids harboring multiple antimicrobial resistance genes.
    Antimicrob Agents Chemother. 2025 Jul 23:e0169724. doi: 10.1128/aac.01697.
    >> Share

  87. YAMADA AY, de Souza AR, Madalosso G, de Assis DB, et al
    Emergence of carbapenem-resistant Acinetobacter baumannii clonal complex 2 in multiple hospitals in Sao Paulo state, Brazil.
    Antimicrob Agents Chemother. 2025 Jul 23:e0186524. doi: 10.1128/aac.01865.
    >> Share

  88. TUANYOK A, Nakajima C, Noll T, Khan MSR, et al
    Genomic insights into ceftazidime resistance in Burkholderia pseudomallei: discovery of A172T mutation and palindromic GC-rich repeat sequences facilitating penA duplication and amplification.
    Antimicrob Agents Chemother. 2025 Jul 21:e0022025. doi: 10.1128/aac.00220.
    >> Share

  89. TRUONG-BOLDUC QC, Wang Y, Lawton BG, Zweifach JJ, et al
    NorA and Tet38 efflux pumps enable Staphylococcus aureus survival in the cystic fibrosis airway environment, resistance to antibiotics, and coinfection with Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2025 Jul 9:e0046025. doi: 10.1128/aac.00460.
    >> Share

  90. HSU AJ, Tamma PD
    Case Commentary: Overcoming intrinsic resistance-the successful use of aztreonam and avibactam for Stenotrophomonas maltophilia meningitis.
    Antimicrob Agents Chemother. 2025 Jul 9:e0064025. doi: 10.1128/aac.00640.
    >> Share

  91. CANFIELD GS, Chatterjee A, Espinosa J, Mangalea MR, et al
    Correction for Canfield et al., "Lytic Bacteriophages Facilitate Antibiotic Sensitization of Enterococcus faecium".
    Antimicrob Agents Chemother. 2025 Jul 8:e0059025. doi: 10.1128/aac.00590.
    >> Share

  92. CAMARA J, Grau I, Gonzalez-Diaz A, Santos N, et al
    Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact.
    Antimicrob Agents Chemother. 2025 Jul 8:e0023725. doi: 10.1128/aac.00237.
    >> Share

  93. BELLO-LOPEZ E, Kawabata A, Cantero J, Mendoza S, et al
    Genomic epidemiology reveals antibiotic resistance transfer and polyclonal dissemination of Acinetobacter baumannii in a Paraguayan hospital.
    Antimicrob Agents Chemother. 2025 Jul 8:e0007725. doi: 10.1128/aac.00077.
    >> Share

  94. VAN WART SA, Safir MC, Bhavnani SM, Lodise TP, et al
    Population pharmacokinetic analyses for telavancin using data from healthy subjects and patients with infections.
    Antimicrob Agents Chemother. 2025;69:e0138224.
    >> Share

  95. GATTI M, Rinaldi M, Cojutti PG, Bonazzetti C, et al
    A pre-post quasi-experimental study of antimicrobial stewardship exploring the impact of a multidisciplinary approach aimed at attaining an aggressive joint pharmacokinetic/pharmacodynamic target with ceftazidime/avibactam on treatment outcome of KPC-
    Antimicrob Agents Chemother. 2025;69:e0048825.
    >> Share

  96. HOU Y, Pi R, Jia J, Wu Z, et al
    Limited predictive power of known resistance genes for phenotypic drug resistance in clinical Mycobacterium abscessus complex from Beijing in China.
    Antimicrob Agents Chemother. 2025;69:e0184724.
    >> Share

  97. JIA Y, Fan J, Tan Z, Li A, et al
    An enoyl-ACP reductase inhibitor, NITD-916, expresses anti-Mycobacterium abscessus activity.
    Antimicrob Agents Chemother. 2025;69:e0024925.
    >> Share

  98. PITCOCK C, Burgess DS, Olney KB
    Optimizing cefazolin dosing for central nervous system infections: insights from population pharmacokinetics and Monte Carlo simulations.
    Antimicrob Agents Chemother. 2025;69:e0185724.
    >> Share

  99. ZHANG X, Liu F, Li S, Cheng Z, et al
    Evaluating tigecycline dosing for hospital-acquired pneumonia patients: insights from physiologically-based pharmacokinetic modeling of lung exposure.
    Antimicrob Agents Chemother. 2025;69:e0000425.
    >> Share

  100. FERRREIRA CDO, Leturiondo AL, Dos Santos CG, da Silva JB, et al
    Classic and new candidate markers for drug resistance in a large cohort of leprosy patients from the Amazon state, Brazil.
    Antimicrob Agents Chemother. 2025;69:e0155024.
    >> Share

  101. OUTEDA-GARCIA M, Garcia-Pose A, Guijarro-Sanchez P, Rodriguez-Coello A, et al
    The novel polymyxin analogue SPR206 exhibits higher activity than colistin against both colistin-susceptible and colistin-resistant strains of Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025;69:e0194024.
    >> Share

  102. YOO O, Salman S, Hla TK, Osowicki J, et al
    Population pharmacokinetics of penicillin G: insights into increased clearance at low concentrations to guide development of improved long-acting formulations for syphilis and prevention of rheumatic fever.
    Antimicrob Agents Chemother. 2025;69:e0026925.
    >> Share

  103. RAJAKANI SG, Xavier BB, Nguyen NM, Lin Q, et al
    Characterization of genome-wide transpositions induced by colistin exposure in multi-drug-resistant Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2025;69:e0157424.
    >> Share

  104. CALDERIN JM, Wasserman S, Resendiz-Galvan JE, Abdelgawad N, et al
    Population pharmacokinetics of pyrazinamide and isoniazid in plasma and cerebrospinal fluid from South African adults with tuberculous meningitis.
    Antimicrob Agents Chemother. 2025 Jul 1:e0009925. doi: 10.1128/aac.00099.
    >> Share

  105. VAHEDI-SHAHANDASHTI R, Moroder E, Lass-Florl C
    Candida parapsilosis and echinocandins: should the clinical laboratory drop anidulafungin Etest from the susceptibility testing panel?
    Antimicrob Agents Chemother. 2025 Jul 1:e0024125. doi: 10.1128/aac.00241.
    >> Share

    June 2025
  106. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Erratum for Peroutka-Bigus et al., "Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease".
    Antimicrob Agents Chemother. 2025 Jun 26:e0065425. doi: 10.1128/aac.00654.
    >> Share

  107. ERDEM H, Sakir-Yildirim S, Ankarali H, Batirel A, et al
    Managing Candida auris fungemias: the results of a prospective and international study.
    Antimicrob Agents Chemother. 2025 Jun 25:e0035825. doi: 10.1128/aac.00358.
    >> Share

  108. BOYD JM, Price EE, Roman Rodriguez F, Burchat N, et al
    Treatment of Staphylococcus aureus with environmentally relevant concentrations of triclosan activates SaeRS-dependent virulence factor expression.
    Antimicrob Agents Chemother. 2025 Jun 18:e0172824. doi: 10.1128/aac.01728.
    >> Share

  109. AI Q, Wang S, Chen Z, Zheng S, et al
    Synergistic antibacterial activity and prevention of drug resistance of daptomycin combined with fosfomycin against methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2025 Jun 18:e0160924. doi: 10.1128/aac.01609.
    >> Share

  110. MELLETT M, Lawandi A, Caya C, Lee TC, et al
    Antibiotic synergy against Staphylococcus aureus: a systematic review and meta-analysis.
    Antimicrob Agents Chemother. 2025 Jun 17:e0119924. doi: 10.1128/aac.01199.
    >> Share

  111. GONZALEZ-JIMENEZ I, Keniya MV, Aptekmann AA, Quinteros C, et al
    Expression of 1,3-beta-glucan synthase subunits in Candida glabrata is regulated by the cell cycle and growth conditions and at both transcriptional and post-transcriptional levels.
    Antimicrob Agents Chemother. 2025 Jun 17:e0050025. doi: 10.1128/aac.00500.
    >> Share

  112. LEUS IV, Zgurskaya HI
    No two are alike: on the role of Klebsiella pneumoniae permeability barriers in antibiotic susceptibility and persistence.
    Antimicrob Agents Chemother. 2025 Jun 17:e0008525. doi: 10.1128/aac.00085.
    >> Share

  113. MEEKES LM, Heikema AP, Tompa M, Astorga Alsina AL, et al
    Proteogenomic analysis demonstrates increased bla(OXA-48) copy numbers and OmpK36 loss as contributors to carbapenem resistance in Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2025 Jun 13:e0010725. doi: 10.1128/aac.00107.
    >> Share

  114. SUZUKI Y, Kawada-Matsuo M, Thuan VTT, Le MN-T, et al
    D-alanine synthesis and exogenous alanine affect the antimicrobial susceptibility of Staphylococcus aureus.
    Antimicrob Agents Chemother. 2025 Jun 12:e0193624. doi: 10.1128/aac.01936.
    >> Share

  115. TSAI S, Grimes K
    Case Commentary: A herculean effort for Mycobacterium heraklionense-localized azithromycin bead pharmacokinetics.
    Antimicrob Agents Chemother. 2025;69:e0030525.
    >> Share

  116. SHRIVASTAVA A, Singh S, Boorgula GD, Galvez R-A, et al
    Ivacaftor affects the susceptibility of standard-of-care drugs used to treat Mycobacterium abscessus lung disease.
    Antimicrob Agents Chemother. 2025;69:e0003025.
    >> Share

  117. GARBE E, Ullah A, Aldejohann AM, Kurzai O, et al
    In vitro activity of novel antifungals, natamycin, and terbinafine against Fusarium.
    Antimicrob Agents Chemother. 2025;69:e0191324.
    >> Share

  118. VALADEZ A, Zurawska M, Harlan E, Scheetz MH, et al
    Individual target pharmacokinetic/pharmacodynamic attainment rates among cefepime-treated patients admitted to the ICU with hospital-acquired pneumonia with and without ECMO.
    Antimicrob Agents Chemother. 2025;69:e0010225.
    >> Share

  119. WAITES JT, Crabb DM, Ratliff AE, Waites KB, et al
    Antimicrobial susceptibility and genetic mechanisms of resistance of Ureaplasma isolates in North America between 2012 and 2023.
    Antimicrob Agents Chemother. 2025;69:e0186824.
    >> Share

  120. AL HROOT J, Reeder J, Yuan X, Gu K, et al
    Determining an appropriate fosfomycin (ZTI-01) dosing regimen in pneumonia patients by utilizing minimal PBPK modeling and target attainment analysis.
    Antimicrob Agents Chemother. 2025;69:e0186924.
    >> Share

  121. BLERIOT I, Blasco L, Fernandez-Grela P, Fernandez-Garcia L, et al
    Studies in vitro and in vivo of phage therapy medical products (PTMPs) Targeting Clinical Strains of Klebsiella pneumoniae belonging to the clone ST512.
    Antimicrob Agents Chemother. 2025;69:e0193524.
    >> Share

  122. MATEO-VARGAS MA, Rodriguez-Pallares S, Arca-Suarez J, Lopez-Cerero L, et al
    Emergence of KPC-8-producing K. pneumoniae infection without prior exposure to ceftazidime/avibactam: the threat of de novo infections by ceftazidime/avibactam-resistant KPC variants.
    Antimicrob Agents Chemother. 2025;69:e0149424.
    >> Share

  123. DUBORG MIKKELSEN MK, Jorgensen AR, Dahl VN, Wejse CM, et al
    Mycobacterium heraklionense hand tenosynovitis-a case description of a three-year treatment course and perioperative measurement of azithromycin target tissue concentrations.
    Antimicrob Agents Chemother. 2025;69:e0167024.
    >> Share

  124. WONG-SO J, Magreault S, Carbonnelle E, Jullien V, et al
    Aztreonam plus ceftazidime-avibactam for post-neurosurgical meningitis due to Stenotrophomonas maltophilia.
    Antimicrob Agents Chemother. 2025 Jun 2:e0017225. doi: 10.1128/aac.00172.
    >> Share

    May 2025
  125. ARMESILLA-DIAZ A, Pilar Arenaz M, Ashby C, Blanco D, et al
    High-throughput screening of small molecules targeting Mycobacterium tuberculosis in human iPSC macrophages.
    Antimicrob Agents Chemother. 2025 May 27:e0161324. doi: 10.1128/aac.01613.
    >> Share

  126. LIU X, Qu X, Zhang R, Zhang Y, et al
    Synergistic combination of next-generation polymyxin MRX-8 and meropenem against carbapenem-resistant A. baumannii.
    Antimicrob Agents Chemother. 2025 May 27:e0191224. doi: 10.1128/aac.01912.
    >> Share

  127. XIE L, Li J, Peng Q, Liu X, et al
    Contribution of RND superfamily multidrug efflux pumps AdeABC, AdeFGH, and AdeIJK to antimicrobial resistance and virulence factors in multidrug-resistant Acinetobacter baumannii AYE.
    Antimicrob Agents Chemother. 2025 May 23:e0185824. doi: 10.1128/aac.01858.
    >> Share

  128. NELSON ME, Little JL, Kristich CJ
    Correction for Nelson et al., "Pbp4 provides transpeptidase activity to the FtsW-PbpB peptidoglycan synthase to drive cephalosporin resistance in Enterococcus faecalis".
    Antimicrob Agents Chemother. 2025 May 20:e0059425. doi: 10.1128/aac.00594.
    >> Share

  129. HACKEL MA, Karlowsky JA, Sahm DF, West JM, et al
    In vitro activity of gepotidacin against urinary tract infection isolates of Enterobacterales, Enterococcus faecalis, and Staphylococcus saprophyticus.
    Antimicrob Agents Chemother. 2025 May 15:e0029625. doi: 10.1128/aac.00296.
    >> Share

  130. ZEGANS ME, Kamath MM, Jones JT, Bao R, et al
    Propranolol is efficacious against Aspergillus and Fusarium corneal isolates in vitro and in a murine model of Aspergillus keratitis.
    Antimicrob Agents Chemother. 2025 May 15:e0166424. doi: 10.1128/aac.01664.
    >> Share

  131. CEBALLOS-GARZON A, Lebrat J, Holzapfel M, Josa DF, et al
    Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains.
    Antimicrob Agents Chemother. 2025 May 15:e0013725. doi: 10.1128/aac.00137.
    >> Share

  132. LI X, Zhou L, Wang D, Wu Q, et al
    Population pharmacokinetics study on nebulized and intravenous administration of polymyxin B in patients with pneumonia caused by multidrug-resistant gram-negative bacteria.
    Antimicrob Agents Chemother. 2025;69:e0004425.
    >> Share

  133. AUBRY R, Buyck JM, Chauzy A, Prouvensier L, et al
    PKPD modeling of the inoculum effect of combined ceftazidime/avibactam and colistin against KPC-3 Klebsiella pneumoniae isolate.
    Antimicrob Agents Chemother. 2025;69:e0179724.
    >> Share

  134. FLEMING D, Al-Jabri MY, Patel R
    Comparative efficacy of levofloxacin, azithromycin, and doxycycline prophylaxis and treatment in an experimental Ureaplasma murine lung infection model.
    Antimicrob Agents Chemother. 2025;69:e0172424.
    >> Share

  135. SAHA S, RoyChowdhury D, Khan AH, Mandal S, et al
    Harnessing the effect of iron deprivation to attenuate the growth of opportunistic pathogen Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025;69:e0168924.
    >> Share

  136. GEBREMARIAM T, Gu Y, Patterson H, Youssef E, et al
    Efficacy assessments of SF001, a next-generation polyene antifungal, in a neutropenic mouse model of invasive fusariosis.
    Antimicrob Agents Chemother. 2025;69:e0180224.
    >> Share

  137. TIAN X, Jiang T, Dong L, Zhang X, et al
    Population pharmacokinetics and clinical assessment of linezolid in pediatric bacterial infections.
    Antimicrob Agents Chemother. 2025;69:e0129924.
    >> Share

  138. SINGH S, Yotsu R, Nuremberger E, Srivastava S, et al
    Repurposing drugs to advance the treatment of Buruli ulcer.
    Antimicrob Agents Chemother. 2025;69:e0002925.
    >> Share

  139. LACROIX M, Moreau J, Zampaloni C, Bissantz C, et al
    In vitro pharmacokinetic/pharmacodynamic modeling of the effect of mucin on polymyxin B activity against Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025;69:e0153524.
    >> Share

  140. BADRANE H, Nguyen MH, Clancy CJ
    Regulation of phosphatidylinositol-(4,5)-bisphosphate and active-Rho1p levels and distribution is crucial for correct spatio-temporal cytokinesis and echinocandin responses in Candida albicans.
    Antimicrob Agents Chemother. 2025 May 5:e0190024. doi: 10.1128/aac.01900.
    >> Share

    April 2025
  141. SONI H, Tyagi S, Mane K, Shelke AM, et al
    The KasA inhibitor JSF-3285 improves the sterilizing activity of bedaquiline-pretomanid-containing regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 23:e0013025. doi: 10.1128/aac.00130.
    >> Share

  142. LEE J, Lee I, Lee K-B, Lee SS, et al
    Comparative effectiveness and safety of colistin-based versus high-dose ampicillin/sulbactam-based combination therapy for nosocomial pneumonia caused by carbapenem-resistant Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025 Apr 23:e0188024. doi: 10.1128/aac.01880.
    >> Share

  143. ZHANG Y, Zhou B, Kong J, Hu P, et al
    Prevalence and characteristics of tigecycline- and carbapenem-resistant adeN-truncated Acinetobacter baumannii: a genomic epidemiological analysis.
    Antimicrob Agents Chemother. 2025 Apr 23:e0184324. doi: 10.1128/aac.01843.
    >> Share

  144. LI D, Li L, Zhang Y, Cheng K, et al
    Efficacy of novel regimens targeting oxidative phosphorylation in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0001925. doi: 10.1128/aac.00019.
    >> Share

  145. SZEL V, Phelan JE, Georghiou SB, Dolinger DL, et al
    The ahpC c-54t compensatory mutation is not always a valid surrogate for isoniazid resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 22:e0026525. doi: 10.1128/aac.00265.
    >> Share

  146. GOVEL JC, Seabury RW, Asiago-Reddy EA, Gutierrez RL, et al
    Evaluation of shorter versus longer antifungal treatment durations for Candida spp. urinary tract infections among hospitalized adults.
    Antimicrob Agents Chemother. 2025 Apr 22:e0192024. doi: 10.1128/aac.01920.
    >> Share

  147. FUTAMURA Y, Yamamoto K, Uson-Lopez R, Aono H, et al
    Inhibitory effect of copper chelators on the budding in Candida albicans.
    Antimicrob Agents Chemother. 2025 Apr 9:e0003325. doi: 10.1128/aac.00033.
    >> Share

  148. ARDIZZONI E, Mulders W, De Diego Fuertes M, Hayrapetyan A, et al
    Phenotypic and genotypic resistance to bedaquiline in patients with multi-drug-resistant tuberculosis-experiences from Armenia.
    Antimicrob Agents Chemother. 2025 Apr 9:e0183924. doi: 10.1128/aac.01839.
    >> Share

  149. HUANG H, Chen Y, Zhang L, Wan P, et al
    Identification and characterization of a novel major facilitator superfamily (MFS) efflux pump conferring multidrug resistance in Staphylococcus aureus and Staphylococcus epidermidis.
    Antimicrob Agents Chemother. 2025 Apr 7:e0173924. doi: 10.1128/aac.01739.
    >> Share

  150. HA KP, Kumeko EK, Bouloc P
    A small regulatory RNA controls antibiotic adaptation in Staphylococcus aureus by modulating efflux pump expression.
    Antimicrob Agents Chemother. 2025 Apr 3:e0117624. doi: 10.1128/aac.01176.
    >> Share

  151. HUANG Y, Chiaraviglio L, Bode-Sojobi I, Kirby JE, et al
    Triple antimicrobial combinations with potent synergistic activity against M. abscessus.
    Antimicrob Agents Chemother. 2025;69:e0182824.
    >> Share

  152. RIMAL B, Howe RA, Panthi C, Lamichhane G, et al
    The efficacy of a regimen comprising clarithromycin, clofazimine, and bedaquiline in a mouse model of chronic Mycobacterium avium lung infection.
    Antimicrob Agents Chemother. 2025;69:e0185324.
    >> Share

  153. SASTRE-FEMENIA MA, Gomis-Font MA, Oliver A
    Mutant prevention concentrations and phenotypic and genomic profiling of first-step resistance mechanisms to classical and novel beta-lactams in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2025;69:e0194224.
    >> Share

  154. SADER HS, Castanheira M, Arends SJR, Doyle TB, et al
    Antimicrobial susceptibility of Stenotrophomonas maltophilia from United States medical centers (2019-2023).
    Antimicrob Agents Chemother. 2025;69:e0012425.
    >> Share

  155. VEERARAGHAVAN B, Shin E, Bakthavatchalam YD, Manesh A, et al
    A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp.
    Antimicrob Agents Chemother. 2025;69:e0162724.
    >> Share

  156. SAMPER-CATIVIELA C, Torre-Fuentes L, Dieguez-Roda B, Maex M, et al
    Molecular epidemiology of Salmonella Enteritidis in humans and animals in Spain.
    Antimicrob Agents Chemother. 2025;69:e0073824.
    >> Share

  157. WOLFE TM, Jo J, Pinkham NV, Garey KW, et al
    The impact of ibezapolstat and other Clostridioides difficile infection-relevant antibiotics on the microbiome of humanized mice.
    Antimicrob Agents Chemother. 2025;69:e0160424.
    >> Share

  158. MCPHERSON JK, Hurdle JG, Baker ML, Hussain T, et al
    The microbiome-restorative potential of ibezapolstat for the treatment of Clostridioides difficile infection is predicted through variant PolC-type DNA polymerase III in Lachnospiraceae and Oscillospiraceae.
    Antimicrob Agents Chemother. 2025;69:e0167924.
    >> Share

  159. SAWE S, Tsirizani L, Court R, Gausi K, et al
    The effect of pregnancy on the population pharmacokinetics of levofloxacin in South Africans with rifampicin-resistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Apr 1:e0162624. doi: 10.1128/aac.01626.
    >> Share

    March 2025
  160. PEROUTKA-BIGUS N, Brooks EJ, Ramey ME, D'Erasmo H, et al
    Contribution of front-line, standard-of-care drugs to bactericidal responses, resistance emergence, and cure in murine models of easy- or hard-to-treat tuberculosis disease.
    Antimicrob Agents Chemother. 2025 Mar 26:e0190124. doi: 10.1128/aac.01901.
    >> Share

  161. HUANG H, Wan P, Chen Y, Luo X, et al
    Phenotypic and genetic stepwise changes in Staphylococcus aureus during in vitro adaptive laboratory evolution under the selective pressure of tigecycline.
    Antimicrob Agents Chemother. 2025 Mar 26:e0007225. doi: 10.1128/aac.00072.
    >> Share

  162. KIM M-J, Zarnowski R, Jones R, Nett JE, et al
    Vesicle inhibition reduces Candida biofilm resistance.
    Antimicrob Agents Chemother. 2025 Mar 26:e0004525. doi: 10.1128/aac.00045.
    >> Share

  163. MAHE A, Verneuil N, Coupri D, Hartke A, et al
    D-alanylation of lipoteichoic acids inhibitor provides anti-virulence and anti-resistance effects against methicillin-resistant Staphylococcus epidermidis.
    Antimicrob Agents Chemother. 2025 Mar 21:e0182224. doi: 10.1128/aac.01822.
    >> Share

  164. PETERSEN ME, Khamas AB, Ostergaard LJ, Jorgensen NP, et al
    Combination therapy delays antimicrobial resistance after adaptive laboratory evolution of Staphylococcus aureus.
    Antimicrob Agents Chemother. 2025 Mar 14:e0148324. doi: 10.1128/aac.01483.
    >> Share

  165. MUNITA JM, Tamma PD
    Fighting resistance with redundancy: a path forward for treating antimicrobial-resistant infections?
    Antimicrob Agents Chemother. 2025 Mar 14:e0012125. doi: 10.1128/aac.00121.
    >> Share

  166. YU Z, Hu H, Liu X, Liu J, et al
    Clinical outcomes and pharmacokinetics/pharmacodynamics of intravenous polymyxin B treatment for various site carbapenem-resistant gram-negative bacterial infections: a prospective observational multicenter study.
    Antimicrob Agents Chemother. 2025 Mar 6:e0185924. doi: 10.1128/aac.01859.
    >> Share

  167. MACK AR, Hujer AM, Mojica MF, Taracila MA, et al
    beta-Lactamase diversity in Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2025;69:e0078424.
    >> Share

  168. MACK AR, Hujer AM, Mojica MF, Taracila MA, et al
    beta-Lactamase diversity in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2025;69:e0078524.
    >> Share

  169. RIGATOU A, Afolayan AO, Tatsi E-B, Deliolanis I, et al
    Double carbapenemases in Klebsiella pneumoniae blood isolates: dissemination in a single medical center via multiple plasmids and a variety of highly efficient clones.
    Antimicrob Agents Chemother. 2025;69:e0146224.
    >> Share

  170. LEMAITRE N, Dewitte A, Rakotomanimana F, Gooden D, et al
    Assessing the threat of Yersinia pestis harboring a multi-resistant IncC plasmid and the efficacy of an antibiotic targeting LpxC.
    Antimicrob Agents Chemother. 2025;69:e0149724.
    >> Share

  171. ROJAS LJ, Nielsen TB, Pantapalangkoor P, Taracila MA, et al
    Restoring cefepime activity against multidrug-resistant KPC-producing Klebsiella pneumoniae by combination with boronic acid inhibitors, MB076 and S02030.
    Antimicrob Agents Chemother. 2025;69:e0096424.
    >> Share

  172. DORAZIO AJ, Kline EG, Squires KM, Pogue JM, et al
    Restoring ceftolozane susceptibility: a role for diazabicyclooctane beta-lactamase inhibitors?
    Antimicrob Agents Chemother. 2025;69:e0154324.
    >> Share

  173. HAREZA DA, Bergman Y, Jacobs E, Lu J, et al
    Molecular epidemiology of beta-lactamases in ceftriaxone-resistant Enterobacterales bloodstream infections in the mid-Atlantic United States.
    Antimicrob Agents Chemother. 2025;69:e0125824.
    >> Share

  174. MONSIBAIS AN, Tea O, Ghatbale P, Dunham SJB, et al
    Enhanced suppression of Stenotrophomonas maltophilia by a three-phage cocktail: genomic insights and kinetic profiling.
    Antimicrob Agents Chemother. 2025;69:e0116224.
    >> Share

  175. CORNISTEIN W, Balasini C, Nuccetelli Y, Rodriguez VM, et al
    Prevalence and mortality associated with multidrug-resistant infections in adult intensive care units in Argentina (PREV-AR).
    Antimicrob Agents Chemother. 2025;69:e0142624.
    >> Share

  176. VEVE MP, Kenney RM, Aljundi AM, Dierker MS, et al
    Multicenter, retrospective cohort study of antimycobacterial treatment-related harms among patients with non-tuberculosis Mycobacterium infections in the United States.
    Antimicrob Agents Chemother. 2025 Mar 4:e0159624. doi: 10.1128/aac.01596.
    >> Share

    February 2025
  177. YU H, Wang L, Liu X, Zheng J, et al
    Mechanistic insights into the multitarget synergistic efficacy of farrerol and beta-lactam antibiotics in combating methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2025 Feb 28:e0155124. doi: 10.1128/aac.01551.
    >> Share

  178. FU S-Y, Chen X-Z, Yi P-C, Gao J, et al
    Optimizing phage therapy for carbapenem-resistant Enterobacter cloacae bacteremia: insights into dose and timing.
    Antimicrob Agents Chemother. 2025 Feb 26:e0168324. doi: 10.1128/aac.01683.
    >> Share

  179. COJUTTI PG, Gatti M, Tedeschi S, Zamparini E, et al
    Usefulness of a hub and spoke TDM-guided expert clinical pharmacological advice program of dalbavancin for optimizing very long-term curative or suppressive treatment of chronic staphylococcal infections.
    Antimicrob Agents Chemother. 2025 Feb 24:e0183024. doi: 10.1128/aac.01830.
    >> Share

  180. FILE TM JR, Ramirez JA, Wilde AM
    New Perspectives on Antimicrobial Agents: Omadacycline for community-acquired pneumonia, skin and soft tissue infections, and nontuberculous mycobacteria (focus on M. abscessus).
    Antimicrob Agents Chemother. 2025;69:e0108724.
    >> Share

  181. BONCOMPAGNI SR, Riccobono E, Cusi MG, Di Pilato V, et al
    Evidence of dissemination of a clc-type integrative and conjugative element to Stenotrophomonas maltophilia, mediating acquisition of sul1 and other resistance determinants.
    Antimicrob Agents Chemother. 2025;69:e0155424.
    >> Share

  182. TONG DMH, Hughes M-SA, Hu J, Pearson JC, et al
    Comparing two-sample log-linear exposure estimation with Bayesian model-informed precision dosing of tobramycin in adult patients with cystic fibrosis.
    Antimicrob Agents Chemother. 2025;69:e0104024.
    >> Share

  183. CLAEYS KC, Simner PJ, Tekle T, Harris AD, et al
    How accurate is ceftriaxone at predicting susceptibility of enterobacterales isolates to oral higher-generation cephalosporins?
    Antimicrob Agents Chemother. 2025;69:e0138724.
    >> Share

  184. SANCHO-SANCHEZ E, Garcia-Arteaga K, Granados-Chinchilla F, Artavia G, et al
    Reactivation of hidden-latent Brucella infection after doxycycline and streptomycin treatment in mice.
    Antimicrob Agents Chemother. 2025;69:e0130224.
    >> Share

  185. ROSON-CALERO N, Gomis Font MA, Ruiz-Soriano A, Just-Baringo X, et al
    In vitro potentiation of tetracyclines in Pseudomonas aeruginosa by RW01, a new cyclic peptide.
    Antimicrob Agents Chemother. 2025;69:e0145924.
    >> Share

  186. SHIN E, Dousa KM, Taracila MA, Bethel CR, et al
    Durlobactam in combination with beta-lactams to combat Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2025;69:e0117424.
    >> Share

  187. JU Y, Li L, Zhang J, Yusuf B, et al
    The gene MAB_2362 is responsible for intrinsic resistance to various drugs and virulence in Mycobacterium abscessus by regulating cell division.
    Antimicrob Agents Chemother. 2025;69:e0043324.
    >> Share

  188. AMOURA A, Benchetrit L, Magreault S, Chosidow S, et al
    Impact of the inoculum size on the in vivo activity of the aztreonam-avibactam combination in a murine model of peritonitis due to Escherichia coli expressing CTX-M-15 and NDM-1.
    Antimicrob Agents Chemother. 2025;69:e0128822.
    >> Share

  189. ABDUL-AZIZ MH, Diehl A, Liu X, Cheng V, et al
    Population pharmacokinetics of caspofungin in critically ill patients receiving extracorporeal membrane oxygenation-an ASAP ECMO study.
    Antimicrob Agents Chemother. 2025;69:e0143524.
    >> Share

  190. GHEBREKRISTOS Y, Ahmed A, Beylis N, Singh S, et al
    Xpert MTB/RIF Ultra-resistant and MTBDRplus-susceptible rifampicin results in people with tuberculosis: utility of FluoroType MTBDR and deep sequencing.
    Antimicrob Agents Chemother. 2025 Feb 7:e0167124. doi: 10.1128/aac.01671.
    >> Share

    January 2025
  191. SALADO-RASMUSSEN K, Norgaard C, Pedersen TR, Paukner S, et al
    In vitro test of the novel antibiotic lefamulin alone and in combination with doxycycline against Mycoplasma genitalium.
    Antimicrob Agents Chemother. 2025;69:e0134624.
    >> Share

  192. GONG Y, Jiang R, Guo RH, Jo SJ, et al
    TolCV1 inhibition by NPPB renders Vibrio vulnificus less virulent and more susceptible to antibiotics.
    Antimicrob Agents Chemother. 2025;69:e0050224.
    >> Share

  193. FORRISTER NM, McCarty TP, Pappas PG
    New Perspectives on Antimicrobial Agents: Rezafungin.
    Antimicrob Agents Chemother. 2025;69:e0064623.
    >> Share

  194. LI T, Zhu Y, Xiang G, Xu Z, et al
    Adaptive evolution of extensive drug resistance and persistence in epidemic ST11 KPC-producing Klebsiella pneumoniae during antimicrobial chemotherapy.
    Antimicrob Agents Chemother. 2025;69:e0123524.
    >> Share

  195. ABOUELHASSAN Y, Shen Y, Chen A, Ye X, et al
    Ex vivo assessment of sulbactam-durlobactam clearance during continuous renal replacement therapy to guide dosing recommendations.
    Antimicrob Agents Chemother. 2025;69:e0167423.
    >> Share

  196. HE Z, Huang Y, Li W, Zhang H, et al
    Characterization and genomic analysis of the highly virulent Acinetobacter baumannii ST1791 strain dominating in Anhui, China.
    Antimicrob Agents Chemother. 2025;69:e0126224.
    >> Share

  197. QUESILLE-VILLALOBOS AM, Solar C, Martinez JRW, Rivas L, et al
    Multispecies emergence of dual bla(KPC/NDM) carbapenemase-producing Enterobacterales recovered from invasive infections in Chile.
    Antimicrob Agents Chemother. 2025;69:e0120524.
    >> Share

  198. MORITA D, Mukhopadhyay AK, Chowdhury G, Maruyama F, et al
    Genomic epidemiology and genetic characteristics of clinical Campylobacter species cocirculating in West Bengal, India, 2019, using whole genome analysis.
    Antimicrob Agents Chemother. 2025;69:e0110824.
    >> Share

  199. WIEDERHOLD NP, Patterson HP, Ferrer D, Garcia V, et al
    Olorofim demonstrates in vitro activity against Coccidioides species, including isolates against which fluconazole has reduced activity.
    Antimicrob Agents Chemother. 2025;69:e0098824.
    >> Share

  200. NEGATU DA, Aragaw WW, Gebresilase TT, Paruchuri S, et al
    Durlobactam to boost the clinical utility of standard of care beta-lactams against Mycobacterium abscessus lung disease.
    Antimicrob Agents Chemother. 2025;69:e0104624.
    >> Share

  201. GAO L, Wu H, Feng J, Liu Y, et al
    In vitro and in vivo activity of 1,2,3,4,6-O-pentagalloyl-glucose against Candida albicans.
    Antimicrob Agents Chemother. 2025 Jan 24:e0177524. doi: 10.1128/aac.01775.
    >> Share

  202. ZHU Q, Wijnants S, Feil R, Van Genechten W, et al
    The stress-protectant molecule trehalose mediates fluconazole tolerance in Candida glabrata.
    Antimicrob Agents Chemother. 2025 Jan 24:e0134924. doi: 10.1128/aac.01349.
    >> Share

  203. WYNN EA, Dide-Agossou C, Al Mubarak R, Rossmassler K, et al
    Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice.
    Antimicrob Agents Chemother. 2025 Jan 17:e0131024. doi: 10.1128/aac.01310.
    >> Share

  204. VOGENSEN VB, Singh S, Allende CJ, Engelthaler DM, et al
    Fluoroquinolones and rifampin combination in the backdrop of heteroresistant tuberculosis.
    Antimicrob Agents Chemother. 2025 Jan 16:e0108424. doi: 10.1128/aac.01084.
    >> Share

  205. SADER HS, Smart JI, Mendes RE, Castanheira M, et al
    Ceftobiprole activity against multidrug-resistant Staphylococcus aureus clinical isolates collected in the United States from 2016 through 2022.
    Antimicrob Agents Chemother. 2025 Jan 13:e0140224. doi: 10.1128/aac.01402.
    >> Share

    December 2024
  206. JEHANNE Q, Benejat L, Ducournau A, Aptel J, et al
    Increasing rates of erm(B) and erm(N) in human Campylobacter coli and Campylobacter jejuni erythromycin-resistant isolates between 2018 and 2023 in France.
    Antimicrob Agents Chemother. 2024 Dec 31:e0166824. doi: 10.1128/aac.01668.
    >> Share

  207. NDZAMBA B, Denti P, McIlleron H, Smith P, et al
    Pharmacokinetics of ethambutol and weight banded dosing in South African adults newly diagnosed with tuberculosis and HIV.
    Antimicrob Agents Chemother. 2024 Dec 23:e0120024. doi: 10.1128/aac.01200.
    >> Share

  208. OLLINGER TL, Zarnowski R, Parker JE, Kelly SL, et al
    Genetic interaction analysis of Candida glabrata transcription factors CST6 and UPC2A in the regulation of respiration and fluconazole susceptibility.
    Antimicrob Agents Chemother. 2024 Dec 23:e0129424. doi: 10.1128/aac.01294.
    >> Share

  209. ZAGALIOTIS P, Michalik-Provasek J, Mavridou E, Naing E, et al
    Bacteriophage treatment is effective against carbapenem-resistant Klebsiella pneumoniae (KPC) in a neutropenic murine model of gastrointestinal translocation and renal infection.
    Antimicrob Agents Chemother. 2024 Dec 20:e0091924. doi: 10.1128/aac.00919.
    >> Share

  210. GHATBALE P, Sah GP, Dunham S, Khong E, et al
    In vitro resensitization of multidrug-resistant clinical isolates of Enterococcus faecium and E. faecalis through phage-antibiotic synergy.
    Antimicrob Agents Chemother. 2024 Dec 19:e0074024. doi: 10.1128/aac.00740.
    >> Share

  211. MANSJO M, Espinosa-Gongora C, Samanci I, Groenheit R, et al
    Performance of a broth microdilution assay for routine minimum inhibitory concentration determination of 14 anti-tuberculous drugs against the Mycobacterium tuberculosis complex based on the EUCAST reference protocol.
    Antimicrob Agents Chemother. 2024 Dec 18:e0094624. doi: 10.1128/aac.00946.
    >> Share

  212. HIRAYAMA T, Miyazaki T, Tanaka R, Kitahori N, et al
    TAC1b mutation in Candida auris decreases manogepix susceptibility owing to increased CDR1 expression.
    Antimicrob Agents Chemother. 2024 Dec 18:e0150824. doi: 10.1128/aac.01508.
    >> Share

  213. HEINE HS, Purcell BK, Duncan C, Miller L, et al
    Evaluation of a potent LpxC inhibitor for post-exposure prophylaxis treatment of antibiotic-resistant Burkholderia pseudomallei in a murine infection model.
    Antimicrob Agents Chemother. 2024 Dec 13:e0129524. doi: 10.1128/aac.01295.
    >> Share

  214. LEE S, Park S, Kim JN, Lee SO, et al
    Polymorphisms in the type A blaZ gene as determinants of the cefazolin inoculum effect in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2024 Dec 10:e0110624. doi: 10.1128/aac.01106.
    >> Share

  215. KOMM OD, Tyagi S, Garcia A, Almeida D, et al
    Contribution of telacebec to novel drug regimens in a murine tuberculosis model.
    Antimicrob Agents Chemother. 2024 Dec 9:e0096224. doi: 10.1128/aac.00962.
    >> Share

  216. BLANCO-MARTIN T, Gonzalez-Pinto L, Aja-Macaya P, Rodriguez-Pallares S, et al
    Mutant prevention concentrations, in vitro resistance evolution dynamics, and mechanisms of resistance to imipenem and imipenem/relebactam in carbapenem-susceptible Klebsiella pneumoniae isolates showing ceftazidime/avibactam resistance.
    Antimicrob Agents Chemother. 2024;68:e0112024.
    >> Share

  217. SEGERS H, Deville JG, Muller WJ, Manzanares A, et al
    Safety, outcomes, and pharmacokinetics of isavuconazole as a treatment for invasive fungal diseases in pediatric patients: a non-comparative phase 2 trial.
    Antimicrob Agents Chemother. 2024;68:e0048424.
    >> Share

  218. HANSSEN JLJ, van der Wal RJP, Mahdad R, Keizer S, et al
    Targeted antimicrobial regimens for Gram-negative prosthetic joint infections: a prospective multicenter study.
    Antimicrob Agents Chemother. 2024;68:e0123224.
    >> Share

  219. LE TM, Eubank TA, McKelvey AM, Cao X, et al
    Fidaxomicin resistance in Clostridioides difficile: a systematic review and predictive modeling with RNA polymerase binding sites.
    Antimicrob Agents Chemother. 2024;68:e0120624.
    >> Share

  220. ZHAO H, Hu Y, Nie D, Li N, et al
    A peptide targeting outer membrane protein A of Acinetobacter baumannii exhibits antibacterial activity by reducing bacterial pathogenicity.
    Antimicrob Agents Chemother. 2024;68:e0056524.
    >> Share

  221. WU J, Chen C, Luo C, Ning B, et al
    Therapeutic drug monitoring of posaconazole delayed-release tablets and injections in pediatric patients.
    Antimicrob Agents Chemother. 2024;68:e0111224.
    >> Share

  222. RODRIGUEZ-PALLARES S, Blanco-Martin T, Lence E, Aja-Macaya P, et al
    In vivo emergence of resistance to ceftazidime/avibactam through modification of chromosomal AmpC beta-lactamase in Klebsiella aerogenes.
    Antimicrob Agents Chemother. 2024;68:e0130724.
    >> Share

  223. BALDRY M, Costa C, Zeroual Y, Cayet D, et al
    Targeted delivery of flagellin by nebulization offers optimized respiratory immunity and defense against pneumococcal pneumonia.
    Antimicrob Agents Chemother. 2024;68:e0086624.
    >> Share

  224. JACOBS MR, Good CE, Abdelhamed AM, Mack AR, et al
    ARGONAUT-IV: susceptibility of carbapenemase-producing Klebsiella pneumoniae to the oral bicyclic boronate beta-lactamase inhibitor ledaborbactam combined with ceftibuten.
    Antimicrob Agents Chemother. 2024;68:e0112724.
    >> Share

  225. FAN J, Tan Z, He S, Li A, et al
    TBAJ-587, a novel diarylquinoline, is active against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2024;68:e0094524.
    >> Share

  226. XU T, Wu W, Huang L, Liu B, et al
    Novel plasmid-mediated CMY variant (CMY-192) conferring ceftazidime-avibactam resistance in multidrug-resistant Escherichia coli.
    Antimicrob Agents Chemother. 2024;68:e0090624.
    >> Share

  227. ZO S, Choe J, Kim DH, Kim S-Y, et al
    Long-term clinical course of Mycobacterium avium complex pulmonary disease patients with treatment failure.
    Antimicrob Agents Chemother. 2024;68:e0105524.
    >> Share

  228. WANG L, Li Y, Xiu L, Hu L, et al
    Multigeographic clinical assessment of a molecular diagnostic assay for detection of key codons to predict decreased susceptibility or resistance to cephalosporins in Neisseria gonorrhoeae.
    Antimicrob Agents Chemother. 2024;68:e0116524.
    >> Share

  229. MOLASKY NMR, Zhang Z, Gillespie JR, Domagala J, et al
    A novel methionyl-tRNA synthetase inhibitor targeting gram-positive bacterial pathogens.
    Antimicrob Agents Chemother. 2024;68:e0074524.
    >> Share

  230. MELENDEZ JH, Edwards VL, Muniz Tirado A, Hardick J, et al
    Local emergence and global evolution of Neisseria gonorrhoeae with high-level resistance to azithromycin.
    Antimicrob Agents Chemother. 2024;68:e0092724.
    >> Share

    November 2024
  231. VOCAT A, Luraschi-Eggemann A, Antoni C, Cathomen G, et al
    Real-time evaluation of macozinone activity against Mycobacterium tuberculosis through bacterial nanomotion analysis.
    Antimicrob Agents Chemother. 2024 Nov 27:e0131824. doi: 10.1128/aac.01318.
    >> Share

  232. JIA H, Li X, Zhuang Y, Wu Y, et al
    Neural network-based predictions of antimicrobial resistance phenotypes in multidrug-resistant Acinetobacter baumannii from whole genome sequencing and gene expression.
    Antimicrob Agents Chemother. 2024 Nov 14:e0144624. doi: 10.1128/aac.01446.
    >> Share

  233. VEGA LA, Sanson-Iglesias M, Mukherjee P, Buchan KD, et al
    LiaR-dependent gene expression contributes to antimicrobial responses in group A Streptococcus.
    Antimicrob Agents Chemother. 2024 Nov 13:e0049624. doi: 10.1128/aac.00496.
    >> Share

  234. HERRERA C, Gomis-Font MA, Lopez-Causape C, Diez-Aguilar M, et al
    Mechanisms leading to in vivo ceftazidime/avibactam resistance development during treatment of GES-5-producing Pseudomonas aeruginosa infections.
    Antimicrob Agents Chemother. 2024;68:e0116424.
    >> Share

  235. SATTLER J, Ernst CM, Zweigner J, Hamprecht A, et al
    High frequency of acquired virulence factors in carbapenemase-producing Klebsiella pneumoniae isolates from a large German university hospital, 2013-2021.
    Antimicrob Agents Chemother. 2024;68:e0060224.
    >> Share

  236. RIMAL B, Howe RA, Panthi CM, Wang W, et al
    Oral oxaborole MRX-5 exhibits efficacy against pulmonary Mycobacterium abscessus in mouse.
    Antimicrob Agents Chemother. 2024;68:e0135124.
    >> Share

  237. RODVOLD KA, Gotfried MH, Ussery XT, Wong SL, et al
    Intrapulmonary pharmacokinetics of SPR719 following oral administration of SPR720 to healthy volunteers.
    Antimicrob Agents Chemother. 2024;68:e0110324.
    >> Share

  238. PUUMALA E, Nabeela S, Thornburg CC, Grkovic T, et al
    Naamidine A reveals a promising zinc-binding strategy for topical antifungal therapy.
    Antimicrob Agents Chemother. 2024;68:e0119424.
    >> Share

  239. SEREME Y, Faury H, Gravrand V, Ageron E, et al
    Molecular insights into the evolutionary trajectory of a Klebsiella aerogenes clinical isolate with a complex trade-off between resistance and virulence.
    Antimicrob Agents Chemother. 2024;68:e0103624.
    >> Share

  240. MARTIN MJ, Luo TL, Kovalchuk V, Kondratiuk V, et al
    Detection of cefiderocol and aztreonam/avibactam resistance in epidemic Escherichia coli ST-361 carrying bla(NDM-5) and bla(KPC-3) from foreign fighters evacuated from Ukraine.
    Antimicrob Agents Chemother. 2024;68:e0109024.
    >> Share

  241. OKE MT, Martz K, Mocanita M, Knezevic S, et al
    Analysis of Acinetobacter P-type type IV secretion system-encoding plasmid diversity uncovers extensive secretion system conservation and diverse antibiotic resistance determinants.
    Antimicrob Agents Chemother. 2024 Nov 4:e0103824. doi: 10.1128/aac.01038.
    >> Share

    October 2024
  242. LI J, Brandalise D, Coste AT, Sanglard D, et al
    Exploration of novel mechanisms of azole resistance in Candida auris.
    Antimicrob Agents Chemother. 2024 Oct 31:e0126524. doi: 10.1128/aac.01265.
    >> Share

  243. KON H, Lurie-Weinberger MN, Bechor M, Temkin E, et al
    bla(GES)-producing ST654 comprises a quarter of all carbapenem-resistant Pseudomonas aeruginosa in blood isolates from 15 hospitals.
    Antimicrob Agents Chemother. 2024 Oct 31:e0096524. doi: 10.1128/aac.00965.
    >> Share

  244. LEPAK AJ, Massey J, Zarnowski R, Olesen TK, et al
    In vivo pharmacodynamic evaluation of the novel nystatin derivative BSG005 in the invasive candidiasis and invasive pulmonary aspergillosis mouse models.
    Antimicrob Agents Chemother. 2024 Oct 29:e0123424. doi: 10.1128/aac.01234.
    >> Share

  245. SNOBRE J, Meehan CJ, Mulders W, Rigouts L, et al
    Frameshift mutations in the mmpR5 gene can have a bedaquiline-susceptible phenotype by retaining a protein structure and function similar to wild-type Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 24:e0085424. doi: 10.1128/aac.00854.
    >> Share

  246. MA Z, Zeng W, Liu H, Chen H, et al
    Characterization of novel sequence type 12531 and O8:H7 serotype carbapenem-resistant Escherichia coli with strong swimming and intestinal epithelial cell barrier migration abilities.
    Antimicrob Agents Chemother. 2024 Oct 23:e0080524. doi: 10.1128/aac.00805.
    >> Share

  247. LEDGER EVK, Massey RC
    PBP4 is required for serum-induced cell wall thickening and antibiotic tolerance in Staphylococcus aureus.
    Antimicrob Agents Chemother. 2024 Oct 21:e0096124. doi: 10.1128/aac.00961.
    >> Share

  248. MAITRE T, Godmer A, Mory C, Chauffour A, et al
    Levofloxacin activity at increasing doses in a murine model of fluoroquinolone-susceptible and -resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Oct 16:e0058324. doi: 10.1128/aac.00583.
    >> Share

  249. STORER ISR, Sastre-Velasquez LE, Easter T, Mertens B, et al
    Shining a light on the impact of antifungals on Aspergillus fumigatus subcellular dynamics through fluorescence imaging.
    Antimicrob Agents Chemother. 2024 Oct 15:e0080324. doi: 10.1128/aac.00803.
    >> Share

  250. KENT AG, Spicer LM, Campbell D, Breaker E, et al
    Sentinel Surveillance reveals phylogenetic diversity and detection of linear plasmids harboring vanA and optrA among enterococci collected in the United States.
    Antimicrob Agents Chemother. 2024 Oct 15:e0059124. doi: 10.1128/aac.00591.
    >> Share

  251. ZARSKE M, Werckenthin C, Golz JC, Stingl K, et al
    The point mutation A1387G in the 16S rRNA gene confers aminoglycoside resistance in Campylobacter jejuni and Campylobacter coli.
    Antimicrob Agents Chemother. 2024 Oct 15:e0083324. doi: 10.1128/aac.00833.
    >> Share

  252. SALAMA EA, Elgammal Y, Utturkar SM, Lanman NA, et al
    Overcoming amphotericin B resistance in Candida auris using the antiemetic drug rolapitant.
    Antimicrob Agents Chemother. 2024 Oct 10:e0055624. doi: 10.1128/aac.00556.
    >> Share

  253. HONG H, Fan L, Shi W, Zhu Y, et al
    Overexpression of beta-lactamase genes (bla(KPC,) bla(SHV)) and novel CirA deficiencies contribute to decreased cefiderocol susceptibility in carbapenem-resistant Klebsiella pneumoniae before its approval in China.
    Antimicrob Agents Chemother. 2024 Oct 10:e0075424. doi: 10.1128/aac.00754.
    >> Share

  254. BOAST A, Zhang W, Soeorg H, Gonis G, et al
    Population pharmacokinetic modeling of ceftriaxone in cerebrospinal fluid in children: should we be using once- or twice-daily dosing for meningitis?
    Antimicrob Agents Chemother. 2024 Oct 8:e0074724. doi: 10.1128/aac.00747.
    >> Share

  255. HENRIKSEN NL, Serrano-Chavez E, Fuglsang-Madsen A, Jensen LK, et al
    Gentamicin and clindamycin antibiotic-eluting depot technology eradicates S. aureus in an implant-associated osteomyelitis pig model without systemic antibiotics.
    Antimicrob Agents Chemother. 2024;68:e0069124.
    >> Share

  256. GOH JJN, Wang Q, Zhang N, de Castro Suarez N, et al
    Prospectively predicting BPaMZ phase IIb/III trial outcomes using a translational mouse-to-human platform.
    Antimicrob Agents Chemother. 2024;68:e0061524.
    >> Share

  257. KAUR JN, Klem JF, Liu Y, Boissonneault KR, et al
    Maximally precise combinations to overcome metallo-beta-lactamase-producing Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024;68:e0077024.
    >> Share

  258. NUMATA S, Hara T, Izawa M, Okuno Y, et al
    Novel humanized anti-PcrV monoclonal antibody COT-143 protects mice from lethal Pseudomonas aeruginosa infection via inhibition of toxin translocation by the type III secretion system.
    Antimicrob Agents Chemother. 2024;68:e0069424.
    >> Share

  259. LI H, Oliver A, Shields RK, Kamat S, et al
    Molecular characterization of clinically isolated Pseudomonas aeruginosa with varying resistance to ceftazidime-avibactam and ceftolozane-tazobactam collected as a part of the ATLAS global surveillance program from 2020 to 2021.
    Antimicrob Agents Chemother. 2024;68:e0067024.
    >> Share

  260. STURARO MC, Damaceno NdS, Faccin ID, Silva ON, et al
    Synergistic antimicrobial combination of third-generation cephalosporins and polymyxin B against carbapenem-polymyxin-resistant Klebsiella pneumoniae: an in vitro and in vivo analysis.
    Antimicrob Agents Chemother. 2024;68:e0093024.
    >> Share

  261. PLUMET L, Costechareyre D, Lavigne J-P, Kissa K, et al
    Zebrafish as an effective model for evaluating phage therapy in bacterial infections: a promising strategy against human pathogens.
    Antimicrob Agents Chemother. 2024;68:e0082924.
    >> Share

  262. HUANG H, Yang H, Feng S, Zhang X, et al
    High salt condition alters LPS synthesis and induces the emergence of drug resistance mutations in Helicobacter pylori.
    Antimicrob Agents Chemother. 2024;68:e0058724.
    >> Share

  263. RUBIO J, Yan J, Miller S, Cheng J, et al
    Polymyxins retain in vitro activity and in vivo efficacy against "resistant" Acinetobacter baumannii strains when tested in physiological conditions.
    Antimicrob Agents Chemother. 2024;68:e0072524.
    >> Share

  264. SINGH V, Nandanwar H
    IMT-P8 potentiates Gram-positive specific antibiotics in intrinsically resistant Gram-negative bacteria.
    Antimicrob Agents Chemother. 2024;68:e0075324.
    >> Share

  265. HAREZA DA, Cosgrove SE, Bonomo RA, Dzintars K, et al
    Clinical outcomes and emergence of resistance of Pseudomonas aeruginosa infections treated with ceftolozane-tazobactam versus ceftazidime-avibactam.
    Antimicrob Agents Chemother. 2024;68:e0090724.
    >> Share

  266. WOOD GE, Lee JW, Peramuna T, Wendt KL, et al
    The fungal natural product fusidic acid demonstrates potent activity against Mycoplasma genitalium.
    Antimicrob Agents Chemother. 2024;68:e0100624.
    >> Share

  267. ZELMER AR, Yang D, Gunn NJ, Solomon LB, et al
    Osteomyelitis-relevant antibiotics at clinical concentrations show limited effectivity against acute and chronic intracellular S. aureus infections in osteocytes.
    Antimicrob Agents Chemother. 2024;68:e0080824.
    >> Share

  268. GAONA M, Corral J, Campoy S, Barbe J, et al
    The novel MFS efflux pump SxtP, regulated by the LysR-type transcriptional activator SxtR, is involved in the susceptibility to sulfamethoxazole/trimethoprim (SXT) and the pathogenesis of Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2024;68:e0071224.
    >> Share

  269. ALLAIN M, Morel-Journel T, Condamine B, Gibeaux B, et al
    IncC plasmid genome rearrangements influence the vertical and horizontal transmission tradeoff in Escherichia coli.
    Antimicrob Agents Chemother. 2024;68:e0055424.
    >> Share

  270. DUBEY V, Farrington N, Harper N, Johnson A, et al
    Acinetobacter baumannii transformants expressing oxacillinases and metallo-beta-lactamases that confer resistance to meropenem: new tools for anti-Acinetobacter drug development and AMR preparedness.
    Antimicrob Agents Chemother. 2024;68:e0022224.
    >> Share

  271. XU J-Y, Dong H-h, Liao L-j, Yang S-x, et al
    Deoxyshikonin: a promising lead drug grass against drug resistance or sensitivity to Helicobacter pylori in an acidic environment.
    Antimicrob Agents Chemother. 2024;68:e0095924.
    >> Share

  272. SINTES R, McLellan P, Navelli G, Landman C, et al
    Use of frozen native feces for fecal microbiota transplantation in recurrent Clostridioides difficile infection: a simple way to improve the efficiency of donor feces preparation.
    Antimicrob Agents Chemother. 2024;68:e0073424.
    >> Share

  273. YASMIN M, Marshall SH, Chen L, Rhoads DD, et al
    A molecular analysis of meropenem-vaborbactam non-susceptible KPC-producing Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024;68:e0020824.
    >> Share

  274. TAVAKKOL A, DuBois JC, Gupta AK
    Systemic absorption and safety of topical terbinafine hydrochloride 10% solution (MOB015B): a phase 1 maximal usage trial in patients with moderate-to-severe onychomycosis.
    Antimicrob Agents Chemother. 2024;68:e0068224.
    >> Share

  275. RENDON MA, So M
    Zap the clap with DNA: a novel microbicide for preventing Neisseria gonorrhoeae infection.
    Antimicrob Agents Chemother. 2024;68:e0079424.
    >> Share

  276. FUKUSHIMA K, Matsumoto Y, Abe Y, Hashimoto K, et al
    Variability of macrolide-resistant profile in Mycobacterium avium complex pulmonary disease.
    Antimicrob Agents Chemother. 2024 Oct 8:e0121324. doi: 10.1128/aac.01213.
    >> Share

  277. GUIN S, Montoya MC, Wang X, Zarnowski R, et al
    Analogs of the anti-malaria drug mefloquine have broad-spectrum antifungal activity and are efficacious in a model of disseminated Candida auris infection.
    Antimicrob Agents Chemother. 2024 Oct 4:e0130124. doi: 10.1128/aac.01301.
    >> Share

    September 2024
  278. ENCINAS L, Li S-Y, Rullas-Trincado J, Tasneen R, et al
    Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0035724. doi: 10.1128/aac.00357.
    >> Share

  279. CARVAJAL LP, Rincon S, Gomez Villegas SI, Matiz-Gonzalez JM, et al
    Prevalence of the cefazolin inoculum effect (CzIE) in nasal colonizing methicillin-susceptible Staphylococcus aureus in patients from intensive care units in Colombia and use of a modified rapid nitrocefin test for detection.
    Antimicrob Agents Chemother. 2024 Sep 30:e0089824. doi: 10.1128/aac.00898.
    >> Share

  280. BAUMAN AA, Sarathy JP, Kaya F, Massoudi LM, et al
    Spectinamide MBX-4888A exhibits favorable lesion and tissue distribution and promotes treatment shortening in advanced murine models of tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 30:e0071624. doi: 10.1128/aac.00716.
    >> Share

  281. WASIELEWSKI AS, Casapao AM, Jankowski CA, Isache CL, et al
    Impact of obesity on clinical outcomes of methicillin-susceptible Staphylococcus aureus bloodstream infections.
    Antimicrob Agents Chemother. 2024 Sep 26:e0075224. doi: 10.1128/aac.00752.
    >> Share

  282. MATUSIK E, Vassal O, Conrad A, Ferry T, et al
    Parametric and nonparametric population pharmacokinetic analysis of fluconazole in critically ill patients and dosing simulations for Candida infections.
    Antimicrob Agents Chemother. 2024 Sep 26:e0099124. doi: 10.1128/aac.00991.
    >> Share

  283. ALLEN R, Ames L, Baldin VP, Butts A, et al
    An arylsulfonamide that targets cell wall biosynthesis in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Sep 26:e0103724. doi: 10.1128/aac.01037.
    >> Share

  284. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Erratum for Poonawala et al., "Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis".
    Antimicrob Agents Chemother. 2024 Sep 19:e0135424. doi: 10.1128/aac.01354.
    >> Share

  285. RHODES J, Jacobs J, Dennis EK, Manjari SR, et al
    What makes Candida auris pan-drug resistant? Integrative insights from genomic, transcriptomic, and phenomic analysis of clinical strains resistant to all four major classes of antifungal drugs.
    Antimicrob Agents Chemother. 2024 Sep 19:e0091124. doi: 10.1128/aac.00911.
    >> Share

  286. CASTANHEIRA M, Deshpande LM, Rhomberg PR, Carvalhaes CG, et al
    Recent increase in Candida auris frequency in the SENTRY surveillance program: antifungal activity and genotypic characterization.
    Antimicrob Agents Chemother. 2024 Sep 12:e0057024. doi: 10.1128/aac.00570.
    >> Share

  287. LE RUN E, Tettelin H, Holland SM, Zelazny AM, et al
    Evolution toward extremely high imipenem resistance in Mycobacterium abscessus outbreak strains.
    Antimicrob Agents Chemother. 2024 Sep 10:e0067324. doi: 10.1128/aac.00673.
    >> Share

  288. KOMORI K, Aoki K, Harada S, Ishii Y, et al
    Plasmid-mediated acquisition and chromosomal integration of bla(CTX-M-14) in a subclade of Escherichia coli ST131-H30 clade C1.
    Antimicrob Agents Chemother. 2024;68:e0081724.
    >> Share

  289. BHAVNANI SM, Hammel JP, Lakota EA, Liolios K, et al
    Assessment of pharmacokinetics-pharmacodynamics to support omadacycline dosing regimens for the treatment of patients with acute bacterial skin and skin structure infections.
    Antimicrob Agents Chemother. 2024;68:e0128123.
    >> Share

  290. LIU L, Wang L, Liu X, Wang B, et al
    Elucidating the potential of isorhapontigenin in targeting the MgrA regulatory network: a paradigm shift for attenuating MRSA virulence.
    Antimicrob Agents Chemother. 2024;68:e0061124.
    >> Share

    August 2024
  291. MARTINI MC, Alonso MN, Cafiero JH, Xiao J, et al
    Loss of glycerol catabolism confers carbon-source-dependent artemisinin resistance in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Aug 28:e0064524. doi: 10.1128/aac.00645.
    >> Share

  292. TIAN P, Li Q-Q, Guo M-J, Zhu Y-Z, et al
    Zidovudine in synergistic combination with nitrofurantoin or omadacycline: in vitro and in murine urinary tract or lung infection evaluation against multidrug-resistant Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024 Aug 28:e0034424. doi: 10.1128/aac.00344.
    >> Share

  293. MOLENDIJK MM, Boekema BKHL, Lattwein KR, Vlig M, et al
    Bacteriophage therapy reduces Staphylococcus aureus in a porcine and human ex vivo burn wound infection model.
    Antimicrob Agents Chemother. 2024 Aug 13:e0065024. doi: 10.1128/aac.00650.
    >> Share

  294. ROTONDO CM, Wright GD
    Efficacy of aspergillomarasmine A/meropenem combinations with and without avibactam against bacterial strains producing multiple beta-lactamases.
    Antimicrob Agents Chemother. 2024 Aug 12:e0027224. doi: 10.1128/aac.00272.
    >> Share

  295. HEINE HS, Drusano G, Purcell BK, Anastasiou D, et al
    Omadacycline is active in vitro and in vivo against ciprofloxacin-resistant Bacillus anthracis.
    Antimicrob Agents Chemother. 2024 Aug 12:e0059524. doi: 10.1128/aac.00595.
    >> Share

  296. EISHA S, Morris AJ, Martin I, Yau YCW, et al
    Effect of L-arginine on cystic fibrosis Pseudomonas aeruginosa biofilms.
    Antimicrob Agents Chemother. 2024;68:e0033624.
    >> Share

  297. RIMAL B, Lippincott CK, Panthi CM, Xie Y, et al
    Efficacy of epetraborole against Mycobacteroides abscessus in a mouse model of lung infection.
    Antimicrob Agents Chemother. 2024;68:e0064824.
    >> Share

  298. EGGE SL, Rizvi SA, Simar SR, Alcalde M, et al
    Cefiderocol heteroresistance associated with mutations in TonB-dependent receptor genes in Pseudomonas aeruginosa of clinical origin.
    Antimicrob Agents Chemother. 2024;68:e0012724.
    >> Share

  299. PONTA G, Morena V, Strano M, Molteni C, et al
    Safety of rezafungin as a long-term treatment option in two patients with complicated fungal infections: two cases from Lecco Hospital (Italy).
    Antimicrob Agents Chemother. 2024;68:e0075024.
    >> Share

  300. SUN Y, Zhang K, Delos Santos M, Pee CJE, et al
    An optimized cyclophosphamide-treated mouse model of Mycobacterium abscessus pulmonary infection.
    Antimicrob Agents Chemother. 2024;68:e0152023.
    >> Share

  301. WIECZORKIEWICZ JT, Skinner AM, Cheknis A, Petrella LA, et al
    Epidemiology of Clostridioides difficile infection at one hospital 10 years after an outbreak of the epidemic C. difficile strain BI/027: changing strain prevalence, antimicrobial susceptibilities, and patient antibiotic exposures.
    Antimicrob Agents Chemother. 2024;68:e0069824.
    >> Share

    July 2024
  302. NELSON ME, Little JL, Kristich CJ
    Pbp4 provides transpeptidase activity to the FtsW-PbpB peptidoglycan synthase to drive cephalosporin resistance in Enterococcus faecalis.
    Antimicrob Agents Chemother. 2024 Jul 26:e0055524. doi: 10.1128/aac.00555.
    >> Share

  303. ADELMAN MW, Andes DR
    Case Commentary: Extending our therapeutic range against multidrug-resistant Candida.
    Antimicrob Agents Chemother. 2024 Jul 22:e0084724. doi: 10.1128/aac.00847.
    >> Share

  304. ROBERTS AH, Moon CW, Faulkner V, Kendall SL, et al
    EfpA is required for regrowth of Mycobacterium tuberculosis following isoniazid exposure.
    Antimicrob Agents Chemother. 2024 Jul 22:e0026124. doi: 10.1128/aac.00261.
    >> Share

  305. WASSERMAN S, Antilus-Sainte R, Abdelgawad N, Odjourian NM, et al
    Rifabutin central nervous system concentrations in a rabbit model of tuberculous meningitis.
    Antimicrob Agents Chemother. 2024 Jul 19:e0078324. doi: 10.1128/aac.00783.
    >> Share

  306. TRUONG-BOLDUC QC, Wang Y, Lawton BG, Brown Harding H, et al
    Phenazine-1 carboxylic acid of Pseudomonas aeruginosa induces the expression of Staphylococcus aureus Tet38 MDR efflux pump and mediates resistance to phenazines and antibiotics.
    Antimicrob Agents Chemother. 2024 Jul 19:e0063624. doi: 10.1128/aac.00636.
    >> Share

  307. SIMEON S, Garcia-Cremades M, Savic R, Solans BP, et al
    Pharmacokinetic-pharmacodynamic modeling of tuberculosis time to positivity and colony-forming unit to assess the response to dose-ranging linezolid.
    Antimicrob Agents Chemother. 2024 Jul 17:e0019024. doi: 10.1128/aac.00190.
    >> Share

  308. GIGANTE V, Alm RA, Melchiorri D, Rocke T, et al
    Multi-year analysis of the global preclinical antibacterial pipeline: trends and gaps.
    Antimicrob Agents Chemother. 2024 Jul 15:e0053524. doi: 10.1128/aac.00535.
    >> Share

  309. STRAHILEVITZ J, Motro Y, Temper V, Merezhko D, et al
    In vivo selection of carbapenem resistance during persistent Klebsiella pneumoniae sequence type 395 bloodstream infection due to OmpK36 deletion.
    Antimicrob Agents Chemother. 2024 Jul 11:e0066324. doi: 10.1128/aac.00663.
    >> Share

  310. ANTONELLI A, Coppi M, Bonaiuto C, Giovacchini N, et al
    Pseudomonas aeruginosa producing FIM-1-metallo-beta-lactamase: emergence and cross-transmission in a long-term acute care rehabilitation hospital.
    Antimicrob Agents Chemother. 2024;68:e0057424.
    >> Share

  311. LAWRENCE WS, Peel JE, Slayden RA, Peterson JW, et al
    Rapid in vitro activity of telavancin against Bacillus anthracis and in vivo protection against inhalation anthrax infection in the rabbit model.
    Antimicrob Agents Chemother. 2024;68:e0011224.
    >> Share

  312. LIPPINCOTT CK, Lamichhane G
    Case Commentary: Dual beta-lactam as part of regimen to treat Mycobacterium abscessus lung disease.
    Antimicrob Agents Chemother. 2024;68:e0058524.
    >> Share

  313. CLUTTER DS, Samiezade-Yazd Z, Champsi JH, Schapiro J, et al
    Antibiotic duration and route for treatment of adults with uncomplicated streptococcal bloodstream infections: a retrospective study in a large healthcare system.
    Antimicrob Agents Chemother. 2024 Jul 8:e0022024. doi: 10.1128/aac.00220.
    >> Share

  314. BEREDAKI M-I, Arendrup MC, Pournaras S, Meletiadis J, et al
    Comparative pharmacodynamics and dose optimization of liposomal amphotericin B against Candida species in an in vitro pharmacokinetic/pharmacodynamic model.
    Antimicrob Agents Chemother. 2024 Jul 3:e0022524. doi: 10.1128/aac.00225.
    >> Share

    June 2024
  315. KURTZHALS ML, Norman A, Svensson E, Lillebaek T, et al
    Applying whole genome sequencing to predict phenotypic drug resistance in Mycobacterium tuberculosis: leveraging 20 years of nationwide data from Denmark.
    Antimicrob Agents Chemother. 2024 Jun 21:e0043024. doi: 10.1128/aac.00430.
    >> Share

  316. PLUMET L, Magnan C, Ahmad-Mansour N, Sotto A, et al
    The zebrafish embryo model: unveiling its potential for investigating phage therapy against methicillin-resistant Staphylococcus aureus infection.
    Antimicrob Agents Chemother. 2024 Jun 20:e0056124. doi: 10.1128/aac.00561.
    >> Share

  317. REIDENBERG BE, Jenkins SG, Crandon JL, Hurlburt E, et al
    In vitro activity of taurolidine against clinical Candida auris isolates: relevance to catheter-related bloodstream infections.
    Antimicrob Agents Chemother. 2024 Jun 12:e0038124. doi: 10.1128/aac.00381.
    >> Share

  318. MOTTA I, Cusinato M, Ludman AJ, Lachenal N, et al
    How much should we still worry about QTc prolongation in rifampicin-resistant tuberculosis? ECG findings from TB-PRACTECAL clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 6:e0053624. doi: 10.1128/aac.00536.
    >> Share

  319. PETERSIEL N, Giulieri S, Daniel DS, Fan S-H, et al
    Genomic investigation and clinical correlates of the in vitro beta-lactam: NaHCO(3) responsiveness phenotype among methicillin-resistant Staphylococcus aureus isolates from a randomized clinical trial.
    Antimicrob Agents Chemother. 2024 Jun 5:e0021824. doi: 10.1128/aac.00218.
    >> Share

  320. MINUK LM, Brode SK, Mehrabi M, Sharma MK, et al
    Phenotypic amikacin resistance may not indicate poor response to amikacin in Mycobacterium avium complex pulmonary disease.
    Antimicrob Agents Chemother. 2024;68:e0008424.
    >> Share

  321. TANG M, Yao Z, Liu Y, Ma Z, et al
    Host immunity involvement in the outcome of phage therapy against hypervirulent Klebsiella pneumoniae infections.
    Antimicrob Agents Chemother. 2024;68:e0142923.
    >> Share

  322. HERREN SC, Karau MJ, Koscianski CA, Christensen TA, et al
    Phage K exposure generates phage-neutralizing activity in a rabbit model-humoral receptiveness may impact efficacy of phage therapy.
    Antimicrob Agents Chemother. 2024;68:e0005224.
    >> Share

  323. GU X, Lu H, Yang Y, Zhu L, et al
    Could ceftriaxone be a viable alternative to penicillin for the treatment of ocular syphilis?
    Antimicrob Agents Chemother. 2024;68:e0008024.
    >> Share

  324. NEGATU DA, Aragaw WW, Dartois V, Dick T, et al
    A pairwise approach to revitalize beta-lactams for the treatment of TB.
    Antimicrob Agents Chemother. 2024;68:e0003424.
    >> Share

  325. GU Y, Gebremariam T, Alkhazraji S, Youssef E, et al
    Efficacy of an oral lipid nanocrystal formulation of amphotericin B (MAT2203) in the neutropenic mouse model of pulmonary mucormycosis.
    Antimicrob Agents Chemother. 2024;68:e0154023.
    >> Share

  326. TONG Q, Yin C, Hang X, Bai Y, et al
    Loureirin A is a narrow-spectrum antimicrobial agent against Helicobacter pylori.
    Antimicrob Agents Chemother. 2024;68:e0031424.
    >> Share

  327. BROWN-ELLIOTT BA, Bush G, Hughes MD, Rodriguez E, et al
    In vitro activity of gepotidacin and comparator antimicrobials against isolates of nontuberculous mycobacteria (NTM).
    Antimicrob Agents Chemother. 2024;68:e0168423.
    >> Share

  328. BERNARD C, Liu Y, Larrouy-Maumus G, Guilhot C, et al
    Altered serine metabolism promotes drug tolerance in Mycobacterium abscessus via a WhiB7-mediated adaptive stress response.
    Antimicrob Agents Chemother. 2024;68:e0145623.
    >> Share

  329. CHUDEJOVA K, Sourenian T, Palkovicova J, Stredanska K, et al
    Genomic characterization of ST38 NDM-5-producing Escherichia coli isolates from an outbreak in the Czech Republic.
    Antimicrob Agents Chemother. 2024;68:e0013324.
    >> Share

  330. WALSH KF, Lee MH, Zainabadi K, Vilbrun SC, et al
    High variance in quantification of Mycobacterium tuberculosis at low bacterial loads and with differentially detectable mycobacteria.
    Antimicrob Agents Chemother. 2024 Jun 3:e0160123. doi: 10.1128/aac.01601.
    >> Share

    May 2024
  331. HUANG E, Thompson RN, Moon SH, Keck JM, et al
    Treatment-emergent cefiderocol resistance in carbapenem-resistant Acinetobacter baumannii is associated with insertion sequence ISAba36 in the siderophore receptor pirA.
    Antimicrob Agents Chemother. 2024 May 29:e0029024. doi: 10.1128/aac.00290.
    >> Share

  332. GAVIRAGHI A, de Nicolo A, Venuti F, Stroffolini G, et al
    Low azithromycin maximal concentrations in patients concomitantly taking rifampicin: time to move away from rifampicin in the treatment of non-tuberculous mycobacteria?
    Antimicrob Agents Chemother. 2024 May 24:e0023424. doi: 10.1128/aac.00234.
    >> Share

  333. ANOY MMI, Kim W-J, Gelston S, Fleming D, et al
    Evaluation of treatment of methicillin-resistant Staphylococcus aureus biofilms with intermittent electrochemically generated H(2)O(2) or HOCl.
    Antimicrob Agents Chemother. 2024 May 21:e0172223. doi: 10.1128/aac.01722.
    >> Share

  334. BECKEN B, Dousa KM, Johnson JL, Holland SM, et al
    Dual beta-lactam for treatment of pulmonary Mycobacterium abscessus in a child.
    Antimicrob Agents Chemother. 2024 May 17:e0031924. doi: 10.1128/aac.00319.
    >> Share

  335. LUO J, Liu M, Ai W, Zheng X, et al
    Synergy of lytic phage pB23 and meropenem combination against carbapenem-resistant Acinetobacter baumannii.
    Antimicrob Agents Chemother. 2024 May 14:e0044824. doi: 10.1128/aac.00448.
    >> Share

  336. HULTQVIST LD, Andersen JB, Nilsson CM, Jansen CU, et al
    High efficacy treatment of murine Pseudomonas aeruginosa catheter-associated urinary tract infections using the c-di-GMP modulating anti-biofilm compound Disperazol in combination with ciprofloxacin.
    Antimicrob Agents Chemother. 2024 May 8:e0148123. doi: 10.1128/aac.01481.
    >> Share

  337. BERGIN S, Doorley LA, Rybak JM, Wolfe KH, et al
    Analysis of clinical Candida parapsilosis isolates reveals copy number variation in key fluconazole resistance genes.
    Antimicrob Agents Chemother. 2024 May 7:e0161923. doi: 10.1128/aac.01619.
    >> Share

  338. VEGA AD, DeRonde K, Jimenez A, Piazza M, et al
    Difficult-to-treat (DTR) Pseudomonas aeruginosa harboring Verona-Integron metallo-beta-lactamase (bla(VIM)): infection management and molecular analysis.
    Antimicrob Agents Chemother. 2024;68:e0147423.
    >> Share

  339. KHALID SA, Abd Algaffar S, Tajuddeen N, Lombe BK, et al
    Naphthylisoquinoline alkaloids: novel agents against the causative pathogens of eumycetoma and actinomycetoma-en route to broad-spectrum antimycetomal drugs.
    Antimicrob Agents Chemother. 2024;68:e0161223.
    >> Share

  340. HAYNES AS, Wei Z, Anderson P, Scheetz MH, et al
    Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections.
    Antimicrob Agents Chemother. 2024;68:e0018224.
    >> Share

  341. MILLER AA, Moussa SH, McLeod SM
    Characterization of Acinetobacter baumannii-calcoaceticus complex isolates and microbiological outcome for patients treated with sulbactam-durlobactam in a phase 3 trial (ATTACK).
    Antimicrob Agents Chemother. 2024;68:e0169823.
    >> Share

  342. MARTINS-GONCALVES T, Pimenta JS, Fontana H, Esposito F, et al
    Acinetobacter baumannii international clone 2 co-producing OXA-23, NDM-1, and ArmA emerging in South America.
    Antimicrob Agents Chemother. 2024;68:e0029824.
    >> Share

  343. CHEN L, Shashkina E, Kurepina N, Calado Nogueira de Moura V, et al
    In vitro activity of cefoxitin, imipenem, meropenem, and ceftaroline in combination with vaborbactam against Mycobacterium abscessus.
    Antimicrob Agents Chemother. 2024;68:e0017424.
    >> Share

  344. GEBREMARIAM T, Alkhazraji S, Gu Y, Najvar LK, et al
    Ibrexafungerp is efficacious in a neutropenic murine model of pulmonary mucormycosis as monotherapy and combined with liposomal amphotericin B.
    Antimicrob Agents Chemother. 2024;68:e0154523.
    >> Share

  345. PHAM J, Benefield RJ, Baker N, Lindblom S, et al
    In vitro activity of omadacycline against clinical isolates of Nocardia.
    Antimicrob Agents Chemother. 2024;68:e0168623.
    >> Share

  346. MUHLEN S, Heroven AK, Elxnat B, Kahl S, et al
    Infection and antibiotic-associated changes in the fecal microbiota of C. rodentium varphistx2(dact)-infected C57BL/6 mice.
    Antimicrob Agents Chemother. 2024;68:e0005724.
    >> Share

  347. BARCELO IM, Escobar-Salom M, Cabot G, Perello-Bauza P, et al
    Transferable AmpCs in Klebsiella pneumoniae: interplay with peptidoglycan recycling, mechanisms of hyperproduction, and virulence implications.
    Antimicrob Agents Chemother. 2024;68:e0131523.
    >> Share

  348. SUZUKI D, Sakurai A, Wakuda M, Suzuki M, et al
    Clinical and genomic characteristics of IMP-producing Enterobacter cloacae complex and Klebsiella pneumoniae.
    Antimicrob Agents Chemother. 2024;68:e0167223.
    >> Share

  349. NIELSEN TK, Petersen IB, Xu L, Barbuti MD, et al
    The Spx stress regulator confers high-level beta-lactam resistance and decreases susceptibility to last-line antibiotics in methicillin-resistant Staphylococcus aureus.
    Antimicrob Agents Chemother. 2024 May 1:e0033524. doi: 10.1128/aac.00335.
    >> Share

  350. YU W, Ju Y, Han X, Tian X, et al
    Bactericidal and sterilizing activity of sudapyridine-clofazimine-TB47 combined with linezolid or pyrazinamide in a murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 May 1:e0012424. doi: 10.1128/aac.00124.
    >> Share

    April 2024
  351. BEN-SHMUEL A, Glinert I, Sittner A, Bar-David E, et al
    Doxycycline, levofloxacin, and moxifloxacin are superior to ciprofloxacin in treating anthrax meningitis in rabbits and NHP.
    Antimicrob Agents Chemother. 2024 Apr 30:e0161023. doi: 10.1128/aac.01610.
    >> Share

  352. PETRAITIS V, Petraitiene R, Kavaliauskas P, Naing E, et al
    Development of rabbit models of ventilator-associated bacterial pneumonia produced by carbapenem-resistant Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024 Apr 30:e0020524. doi: 10.1128/aac.00205.
    >> Share

  353. SHAFER WM, Conn GL
    Ensuring a sustained workforce to combat antibiotic resistance in the 21st century: the critical need for training the next-gen of scientists at the pre-doctoral level.
    Antimicrob Agents Chemother. 2024 Apr 19:e0024424. doi: 10.1128/aac.00244.
    >> Share

  354. HARTUIS S, Ourliac-Garnier I, Robert E, Albassier M, et al
    Precise genome editing underlines the distinct contributions of mutations in ERG11, ERG3, MRR1, and TAC1 genes to antifungal resistance in Candida parapsilosis.
    Antimicrob Agents Chemother. 2024 Apr 16:e0002224. doi: 10.1128/aac.00022.
    >> Share

  355. KENGO A, Nabeemeeah F, Denti P, Sabet R, et al
    Assessing potential drug-drug interactions between clofazimine and other frequently used agents to treat drug-resistant tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 10:e0158323. doi: 10.1128/aac.01583.
    >> Share

  356. LOSSOUARN J, Beurrier E, Bouteau A, Moncaut E, et al
    The virtue of training: extending phage host spectra against vancomycin-resistant Enterococcus faecium strains using the Appelmans method.
    Antimicrob Agents Chemother. 2024 Apr 9:e0143923. doi: 10.1128/aac.01439.
    >> Share

  357. POONAWALA H, Zhang Y, Kuchibhotla S, Green AG, et al
    Transcriptomic responses to antibiotic exposure in Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Apr 8:e0118523. doi: 10.1128/aac.01185.
    >> Share

  358. WEI X, Gao J, Zhou D, Xu C, et al
    Murepavadin promotes the killing efficacies of aminoglycoside antibiotics against Pseudomonas aeruginosa by enhancing membrane potential.
    Antimicrob Agents Chemother. 2024;68:e0153923.
    >> Share

  359. ASLAM S, Roach D, Nikolich MP, Biswas B, et al
    Pseudomonas aeruginosa ventricular assist device infections: findings from ineffective phage therapies in five cases.
    Antimicrob Agents Chemother. 2024;68:e0172823.
    >> Share

  360. GSCHWIND R, Petitjean M, Fournier C, Lao J, et al
    Inter-phylum circulation of a beta-lactamase-encoding gene: a rare but observable event.
    Antimicrob Agents Chemother. 2024;68:e0145923.
    >> Share

  361. XUE J, Li W, Zhao Y, Wang L, et al
    Antibiotic-induced ROS-mediated Fur allosterism contributes to Helicobacter pylori resistance by inhibiting arsR activation of mutS and mutY.
    Antimicrob Agents Chemother. 2024;68:e0167923.
    >> Share

  362. RIBEIRO DOS SANTOS A, Gade L, Misas E, Litvintseva AP, et al
    Bimodal distribution of azole susceptibility in Sporothrix brasiliensis isolates in Brazil.
    Antimicrob Agents Chemother. 2024;68:e0162023.
    >> Share

  363. TAIT JR, Anderson D, Nation RL, Creek DJ, et al
    Identifying and mathematically modeling the time-course of extracellular metabolic markers associated with resistance to ceftolozane/tazobactam in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024;68:e0108123.
    >> Share

  364. YANO H, Hayashi W, Kawakami S, Aoki S, et al
    Nationwide genome surveillance of carbapenem-resistant Pseudomonas aeruginosa in Japan.
    Antimicrob Agents Chemother. 2024 Apr 2:e0166923. doi: 10.1128/aac.01669.
    >> Share

    March 2024
  365. LOCKE JB, Pillar CM, Castanheira M, Carvalhaes CG, et al
    Outcomes by Candida spp. in the ReSTORE Phase 3 trial of rezafungin versus caspofungin for candidemia and/or invasive candidiasis.
    Antimicrob Agents Chemother. 2024 Mar 25:e0158423. doi: 10.1128/aac.01584.
    >> Share

  366. MAIA AR, Cezard A, Fouquenet D, Vasseur V, et al
    Preventive nasal administration of flagellin restores antimicrobial effect of gentamicin and protects against a multidrug-resistant strain of Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024 Mar 25:e0136123. doi: 10.1128/aac.01361.
    >> Share

  367. SEGAWA T, Masuda K, Hisatsune J, Ishida-Kuroki K, et al
    Genomic analysis of inter-hospital transmission of vancomycin-resistant Enterococcus faecium sequence type 80 isolated during an outbreak in Hiroshima, Japan.
    Antimicrob Agents Chemother. 2024 Mar 20:e0171623. doi: 10.1128/aac.01716.
    >> Share

  368. SUN L, Zhuang H, Chen M, Chen Y, et al
    Vancomycin heteroresistance caused by unstable tandem amplifications of the vanM gene cluster on linear conjugative plasmids in a clinical Enterococcus faecium.
    Antimicrob Agents Chemother. 2024 Mar 20:e0115923. doi: 10.1128/aac.01159.
    >> Share

  369. LYONS MA, Obregon-Henao A, Ramey ME, Bauman AA, et al
    Use of multiple pharmacodynamic measures to deconstruct the Nix-TB regimen in a short-course murine model of tuberculosis.
    Antimicrob Agents Chemother. 2024 Mar 19:e0101023. doi: 10.1128/aac.01010.
    >> Share

  370. VILLELLAS C, Stevenaert F, Remmerie B, Andries K, et al
    Sub-MIC levels of bedaquiline and clofazimine can select Mycobacterium tuberculosis mutants with increased MIC.
    Antimicrob Agents Chemother. 2024 Mar 12:e0127523. doi: 10.1128/aac.01275.
    >> Share

  371. HILLIARD JJ, Jakielaszek C, Mannino F, Hossain M, et al
    Efficacy of therapeutically administered gepotidacin in a rabbit model of inhalational anthrax.
    Antimicrob Agents Chemother. 2024;68:e0149723.
    >> Share

  372. HOSODA K, Koyama N, Shigeno S, Nishimura T, et al
    Mavintramycin A is a promising antibiotic for treating Mycobacterium avium complex infectious disease.
    Antimicrob Agents Chemother. 2024;68:e0091723.
    >> Share

  373. ZHANG X, Wang Y, Li S, Xie F, et al
    Simulated drug disposition in critically ill patients to evaluate effective PK/PD targets for combating Pseudomonas aeruginosa resistance to meropenem.
    Antimicrob Agents Chemother. 2024;68:e0154123.
    >> Share

  374. ANDRE C, Van Camp AG, Ung L, Gilmore MS, et al
    Characterization of the resistome and predominant genetic lineages of Gram-positive bacteria causing keratitis.
    Antimicrob Agents Chemother. 2024;68:e0124723.
    >> Share

  375. DUREJA C, Rutherford JT, Pavel FB, Norseeda K, et al
    In vivo evaluation of Clostridioides difficile enoyl-ACP reductase II (FabK) inhibition by phenylimidazole unveils a promising narrow-spectrum antimicrobial strategy.
    Antimicrob Agents Chemother. 2024;68:e0122223.
    >> Share

  376. SALILLAS S, Raaijmakers J, Aarnoutse RE, Svensson EM, et al
    Clofazimine as a substitute for rifampicin improves efficacy of Mycobacterium avium pulmonary disease treatment in the hollow-fiber model.
    Antimicrob Agents Chemother. 2024;68:e0115723.
    >> Share

  377. KOTTOM TJ, Carmona EM, Limper AH
    Characterization of the Pneumocystis jirovecii and Pneumocystis murina phosphoglucomutases (Pgm2s): a potential target for Pneumocystis therapy.
    Antimicrob Agents Chemother. 2024;68:e0075623.
    >> Share

  378. CARUSO L, Mellini M, Catalano Gonzaga O, Astegno A, et al
    Hydrogen sulfide production does not affect antibiotic resistance in Pseudomonas aeruginosa.
    Antimicrob Agents Chemother. 2024 Mar 6:e0007524. doi: 10.1128/aac.00075.
    >> Share

    February 2024
  379. SARANGI J, Ido A, Ito M, Iinuma C, et al
    Clinical isolates of Streptococcus mitis/oralis-related species with reduced carbapenem susceptibility, harboring amino acid substitutions in penicillin-binding proteins in Japan.
    Antimicrob Agents Chemother. 2024 Feb 28:e0117923. doi: 10.1128/aac.01179.
    >> Share

  380. OLIVENCA F, Pires D, Silveiro C, Gama B, et al
    Ethambutol and meropenem/clavulanate synergy promotes enhanced extracellular and intracellular killing of Mycobacterium tuberculosis.
    Antimicrob Agents Chemother. 2024 Feb 27:e0158623. doi: 10.1128/aac.01586.
    >> Share

  381. BASSERES E, Eubank TA, Begum K, Alam MJ, et al
    Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile.
    Antimicrob Agents Chemother. 2024 Feb 16:e0162123. doi: 10.1128/aac.01621.
    >> Share

    January 2024
  382. JIANG X, Li D, Sun Z, Lu Y, et al
    Type I BREX system defends against antibiotic-resistant plasmids in Escherichia coli.
    Antimicrob Agents Chemother. 2024 Jan 30:e0112823. doi: 10.1128/aac.01128.
    >> Share

  383. IOVLEVA A, McElheny CL, Fowler EL, Cober E, et al
    In vitro activity of sulbactam-durlobactam against colistin-resistant and/or cefiderocol-non-susceptible, carbapenem-resistant Acinetobacter baumannii collected in U.S. hospitals.
    Antimicrob Agents Chemother. 2024 Jan 30:e0125823. doi: 10.1128/aac.01258.
    >> Share


Free Medical Abstracts
Privacy Policy
Sponsors
Share

© Amedeo 1997-2016